OPTICALLY ACTIVE ACYLATED CEPHALOSPORIN ANALOGS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

Abstract: Optically active acylated cephalosporin analogs represented by the general formula (I) wherein R₁ represents a hydrogen or a lower alkyl group, R₂ represents a hydrogen or a halogen atom, R₃ represents a hydrogen or a protective group of carboxylic acid, X represents an acyl group represented by the formula X₁CO, are useful as antibacterial agents and methods for preparing such compounds.

Description: Background of the Invention The present invention relates to optically active cephalosporin analogs and, more particularly, it pertains to optically active compounds of cephalosporin analogs represented by the general formula (I) EMI1.1 wherein R1 represents a hydrogen or a lower alkyl group, R2 represents a hydrogen or a halogen atom, R3 represents a hydrogen or a protective group of carboxylic acid, X represents an acvl group represented by the formula XlCO wherein X1 represents the following two gro- ps: : 1) a group represented by the general formula EMI1.2 [wherein B represents an unsaturated six membered carbocycle which is selected from cyclohexenyl group, cyclohexadienyl group and phenyl group or a five or six membered heterocycle, A1 represents substituent(s) which is selected from hydrogen atom, hydroxyl group, a lower alkoxy group having 1 to 4 carbon atoms, a halo group, nitro group, amino group, aminomethyl group, methylsulfonamido group and a lower acyloxy group having 1 to 4 carbon atoms, n is a number from O to 5, and A2 represents amino group, hydroxyl group, carboxyl group or sulfo group). 2) a group represented by the general formula EMI2.1 [wherein A1, B and n have the same significance as defined above and A3 represents hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, a lower alkenyl group having 2 to 6 carbon atoms, a lower alkinyl group having 2 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms or an aryl group, those groups being unsubstituted or substituted wit suitable substituent(s) which is selected from carboxyl group, cyano group, a halo group, carbamoyl group and a lower alkyloxycarbonyl group having 1 to 5 carbon atoms,a cycloalkyl group, an alkenyl groups an alkinyl group, an aryl group, an acyl group having 1 to 5 carbon atoms), and the hydrogens at the 6- and 7-positions have cis configuration and phar-aceutically acceptable salts thereof. A carbaccephem compound, which is named according to the nomenclature in J. Am. Chem. Soc. 96, 7584 (1974), wherein the sulfur atom of cephalosporin is substituted with a carbon atom and which has a substitued methyl group at the 3-position is described in the above reference and 3. Med. Chem. 20, 551 (1977). However, no compound having antibacterial activity has been reported. In Japanese Published Unexamined Patent Application No 9296/79 (German Offenlegungsschrift No. 2716707), compound represented by the general formula (I) wherein R1 and R2 are a hydrogen, X is 2-amino-4-thiazolyl-2-syn-methoxyiminoacetyl group are mentioned but practical embodiment about examples for preparing the compounds and antibacterial activities thereof are not described in the reference. The present inventors have succeeded in preparing carbacephem compounds having various substituents at the 4-, 5- or 3-position. [numbering system is as shown in general formula (I)3 The compounds are described in the specifications of Japanese Unexamined Published Patent Application No. 128591/79 (German Offenlegungsschrift No. 2911786) and Japanese Patent Applications No. 162008/78. Further, the present inventors have succeeded in preparing novel acylated carbacephems which are new antibiotics having strong antibacterial activities. The compounds are described in the specification of Japanese Patent Appli- cations No. 34696/78, 122402/78, 127027/78, 133071/78, 162006/78, 162007/78, and 8409/79 (German Offenlegungsschrift No. 2911787) and Japanese Patent Application No. 162008/7". Among the compounds which were provided by the present inventors and represented by the general formula (II) EMI3.1 (wherein X' is a conventional acyl group employed in the chemistry of cephalosporins and penicillins, R'1 represents hydrogen atom, a lower alkyl group or lower acyloxy group, R'3 represents hydrogen atom or an ester-protecting group conventionally employed in the field of the chemistry of penicillins and cephalosporins, that is, an alkyl group having 1 to 5 carbon atoms such as methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, t-butyl group,etc., a halogenated alkyl group having 1 to 5 carbon atoms such as chloromethyl group, 2,2,2trichloroethyl group, 2,2,2-trifluoroethyl group,etc., an arylmethyl group having 7 to 20 carbon atoms such as benzyl group, diphenylmethyl group, triphenylmethyl group, etc., an arylmethyl group having 7 to 20 carbon atoms and having methoxy-group, nitro group, etc., on the phenyl ring, a substituted silyl group such as trimethylsilyl group or triphenylsilyl group or a group enzymatically or nonenzymaticallv readily eliminable in vivo, for example, a group represented by the general formula -CHOCOR4 wherein R5 represents hydrogen R5 atom or a lower alkyl group having 1 to 6 carbon atoms, R4 represents a lower alkyl group having 1 to 6 carbon atoms, a lower alkoxy group having 1 to 6 carbon atoms or phenyl group, etc. and R2 has the same meaning as defined above) , the acyl compound represented by the formula (I) EMI4.1 (wherein R1, R2 R3 and X have the same meaning as defined above) which has the carbacephem ring represented by the formula (I II) (mentioned below) are reported to have strong antimicrobial activity against Gram-positive and Gramnegative microorganisms in Japanese Patent Applications No. 122402/78, 133071/78, 162006/78, 162007/78 (German Offenlegungsschrift 2911787) etc. Especially the acyl compounds having the carbacephem ring represented by the general formula (I') EMI4.2 wherein A3 has the same significance as defined above, R represents a hydrogen or a methyl group and OA3 has syn configuration, are reported to have strong antimicrobial activity against Gram-positive and Gram-negative microorganisms in the aforementioned patents' applications. Hereinafter, compounds represented by the general formula (I), (II) , (III), are named Compound [I3, Compound [II] , Compound [III] , ...., respectively. However, cephalosporin analogs mentioned above are prepared by totally synthetic methods using optically inactive starting compounds, and they are almost optically inactive dl-compounds except for a compound having a certain optically active acyl group for example D-phenylglycine, etc. described in the specification of Japanese Patent Application No. 162006/78 (German Offenlegungsschrift 2911787). Accordingly, there is a demand for optically active analogs and methods for production thereof. To this end, it has now been found that certain optically active cephalosporin compounds can be prepared which have unexpectedly increased biological activity. Summary of the Invention In accordance with the present invention optically active acyl compounds represented by the formula (I) above are prepared from optically active compounds of the cephalosporin analogs represented by the general formula (III) EMI5.1 (wherein R1, R2 and R3 have the same significance as defined above 'and hydrogens at the 6- and 7-positions have cis configuration). The compounds of the present invention have unexpectedly greater antibacterial activity, i.e. 2 to 4 times greater activity against various Gram-positive and Gram-negative microorganisms than the corresponding optically inactive dl-Compound [I) - Processes of producing optically active Compound [III] are described in detail in Reference Examples 9 to 11. The present applicant filed simultaneously an application relating to the optically active Compound [III] and processes of producing thereof. Further, additional to the known conventional acylating methods, the present inventors succeeded in preparing the some desired compounds by optically selective acylation method, that is, the present inventors succeeded in preparing optically active cephalosporin analogs represented by the general formula (IV) EMI6.1 (wherein R6 represents a substituted or unsubstituted saturated or unsaturated six-membered carbocyclic or five membered heterocyclic group, R1, R2 and R3 have the same meanings defined above, Y represents a lower alkyl group, a hydroxy group, a carboy group or an amino group, and the hydrogens at the 6- and 7-positions have cis configuration) by reacting optically inactive compound [III] or optically active compounds or the cephalosporin analogs represented by the following assumed absolute structural formula (111-1) EMI6.2 (wherein R1, , R2, and R3 have the same meaning as defined above) with a,a-disubstituted carboxylic acid represented by the formula (V) EMI7.1 (wherein R6 and Y have the same meaning as defined above or functionally equivalent reactive derivative in the presence of (1) a microorganism having an ability of pro ducing optically active compounds of the cephalosporin analog represented by the general formula (IV), from the a,a-disubstituted carboxylic acid or reactive derivative thereof and the compound represented by the general formula (III) or (III-1) and belonging to the genus Pseudomonas, Xanthomonas, Escherichia, Aeromonas, Achromobacter, Arthro bacter, Acetobacter, Alcaligenes, Kluyvera, Gluconobacter, Clostridium, Comamonas, Corynebacterium, Sarcina, Staphylo coccus, Spirillum., Bacillus, Flavobacterium, Brevibacterium, Protaminobacter, Beneckea, Micrococcus, Proteus, tlycoplana or Rhodopseudomonas, (2) a culture broth of the microorganism, (3) a treated matter of the culture broth or (4) an enzyme produced by the microorganism and have completed the present invention. Optically inactive dl-compounds corresponding to Compound (III) are present as a mixture of equal amounts of optical isomers (III-1) and (III-2) which are mirror images of each other (enantiomers). EMI7.2 wherein R1, R2 and R3 have the same significance as defined above. The optically active compounds obtained by the processes in Reference Examples below are assumed to have the absolute structure represented by the general formula (III-l) defined above from various properties, strong antimicrobial activity of the acyl compounds compared with the corresponding optically inactive dl-compound and the relation ship between the absolute structure of cephalosporins and activities thereof. In the following, the optically active compounds are described as having the absolute configuration of (6R, 7S), i.e. the configuration illustrated by the general formula (111-1) and in the following Examples and Reference Examples, the compounds are named according to the assumed absolute structural formula, It is needless to say that the optically active eo^nounds are more useful as medicines and antimicrobial agents compared with optically inactive compounds and the compounds of the present invention are, therefore, useful as antibacterial agents which may be employed in manners well known in the art. Detailed Description of the Invention Optically active cephalosporin analogs, according to the. present invention, are represented by the general formula (I) EMI8.1 R1 represents a hydrogen or a lower alkyl group having 1 to 5 carbon atoms such as methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, i-butyl group, t-butyl group, and the like are exemplified. Particularly, methyl group is preferred. Further, it is preferable that the methyl group has the same configuration as the hydrogen atoms at the 6- and 7-psotions, i.e. 4a-configuration in the structural formula (111-1). However, the compounds having 4methyl group and the mixed compounds of 4a- and 4methyl compounds are valuable enough. As group R2, a hydrogen or a halogen atom which is selected from chlorine, bromine or iodine atom is exempli- fied. R3 is a hydrogen or a protective group of carboxylic acid used in the chemistry of penicillins and cephalosporins As group R3, the following are exemplified. 1. straight or branched alkyl group having 1 to 5 carbon atoms such as methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, i-butyl group, t-butyl group, and the like. 2. straight or branched lower alkoxymethyl group having 1 to 5 carbon atoms such as methoxymethyl group, ethoxymethyl group, and the like. 3. straight or branched halogenated alkyl group having 1 to 5 carbon atoms such as chloromethyl group, 2,2,2-trichloromethyl group, 2,2,2-trifuloroethyl group, and the like. 4. lower alkylsulfonylethyl group such as methylsulfonylethyl group, ethylsulfonylethyl group, and the like. 5. arylmethyl group having 7 to 1.2 carbon atoms such as benzyl group, diphenylmethyl group, trityl group, triphenylmethyl group, and the like. 6. substituted silyl group such as trimethylsilyl group, triphenylsilyl group, and the like. 7. substituted arylmethyl group having 7 to 20 carbon atoms wherein the substituent is methoxy group, or nitro group and number of substituents on the phenyl ring is 1 to 5. 8. protective group of carboxylic acid represented by the general formula (VI) EMI10.1 wherein R4 is a straight or branched lower alkyl group having 1 to 6 carbon atoms, a straight or branched lower alkoxy group having 1 to 6 carbon atoms, or a Dhenyl group, and is a hydrogen or a straight or branched lower alkyl group having 1 to 6 carbon atoms. X represents an acyl group represented by the formula X1CO wherein X1 represents the following two groups: 1) a group represented by the general formula EMI10.2 wherein B represents an unsaturated six membered carbocycle such as cyclohexenyl group, cyclohexadienyl group, phenyl group, etc. or a Tive or six membered heterocycle such as furyl group, thienyl group, pyrrolyl group, thiazolyl group, oxazolyl group, isothiazolyl group, isoxazolyl group, imidazolyl group, pyrazolyl group, triazolyl group, tetrazolyl group, pyridinyl-group, pyrimidinyl group, pyrazinyl group, pyridazinyl group, triazinyl group, 5,6-dihydro-1,4dithin-2-yl group, etc., A1 represents substituent(s) which is selected from hydrogen atom, hydroxyl group, a lower alkoxy group having 1 to 4 carbon atoms, a halo group, nitro group-, amino group, aminomethyl group, methylsu)fonamide group, a lower acyloxy group having 1 to 4 carbon atoms, n is a number from 0 to 5, and A2 represents amino group, hydroxyl group, carboxyl group or sulfo group 2) a group represented by the general formula EMI10.3 therein A1, B and n have the same significance as defined above and A3 represents hydrogen atom, a lower alkyl group having'l to 6 carbon atoms, a lower alkenyl group having 2 to 6 carbon atoms, a lower alkinyl group having 2 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms or an aryl group, those groups being unsubstituted or substituted with suitable substituent(s) which is selected from carboxyl group, cyano group, a halo group, carbamoyl group and a lower alkyloxycarbonyl group having 1 to 4 carbon atoms]. In general, it is known that thiazolyl group represented by EMI11.1 shows reversible interconversion with the thiazolinyl group, as shown below, and both are usually regarded as identical. In the presen-t specification, both isomers are represented by thiazolyl group. Of course, Compound [I] includes the both isomers based on the reversible interconversion. EMI11.2 thiazolyl thiazolinyl As for OA3, syn configuration means isomer (A) in the following stereoisomers. EMI11.3 syn (A) anti (B) As the pharmaceutical acceptable salts, salts with inorganic or organic bases, for example, alkali metal salts such as sodium salts, potassium salts, etc., alkali earth metal salts such as magnesium salts, etc., ammonium salts, trimethylamine salts, triethylamine salts, pyridine salts, procaine salts, purine salts, lysine salts, arginine salts, etc. and salts with inorganic or organic acid, for example; hydrochloride, sulfate, carbonate, phosphate, formate, trifluoroacetate, malate, etc. are exemplified. The pharmaceutically acceptable salts are prepared by the standard methods known in the art. The compounds of the present invention are produced by reacting an optically active compounds represented by the general formula (ill-I) EMI12.1 (wherein R1, R2 ant R3 have the same meaning as defined above) or a functionally equivalent compound with carboxylic acid represented by the general formula (VII) X2COOH (VII) (wherein X2 represents the following two groups: 1') a grqup represented by the general formula: : EMI12.2 wherein B and n have the same significance as defined above, Ay represents a substituent which is selected from hydrogen atom, hydroxyl group, a protected hydroxyl group, a lower alkoxy group having 1 to 4 carbon atoms, a halo group, nitro group, a protected amino group, a protected aminomethyl group, methylsulfonamido group and a lower acyloxy group having 1 to 4 carbon atoms, and A'2 represents, a protected amino group, hydroxyl group, a protected.hydroxyl group, carboxyl group, a protected carboxyl group, sulfo group or a protected sulfo group). 2') a group represented by the general formula: EMI13.1 [wherein A'1, B and n have the same significance as defined above and A4 represents hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, a lower alkenyl group having 2 to 6 carbon atoms, a lower alkinyl group having 2 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms or an aryl group, those groups being unsubstituted or substituted with a suitable substituent which is selected from a protected carboxyl group, cyano group, a halo group, carbamoyl group and a lower alkyloxycarbonyl group having 1 to 4 carbon atoms], or with reactive. derivatives of the carboxylic acid and, wherein, optionally deprotecting The protecting group in the group X2CO- and/or -COOR3 and optionally converting to pharmaceutically acceptable salts thereof. A concrete and known acylating method is described in Japanese Unexamined Patent Application No. 122402/53 (German Offenlegungsschrift No. 2911787). Some compounds of the present invention are produced by using optically inactive Compound [1113. In such case an optically tetive Compound [IIIJ is reacted with carboxylic acid represented by the formula (VIII) X3COOH (VIII) wherein X3 represents the following group represented by the formula EMI13.2 wherein A'1 , B and n have the same significance as defined above, A"2 represents protected amino group, hydroxyl group, a protected hydroxyl group, carboxyl group, a protected carboxyl group, sulfo group or protected sulfo group according to the similar method described above in case optically active Compound [III] is used as starting compound and the obtained diastereomeric mixture is separated by conventional method. Further, optically active cephalosporin analogs represented by the general formula (IV) are prepared by optically selective acylation between optically inactive. Compound [III] or optical active Compound [III-1] and Compound IV] in the presence of (1) a microorganism having an ability of producing optically active compounds of the cephalosporin analog represented by the general formula ( from the c',a-disubstituted carboxylic acid or reactive derivative thereof and the compound represented by the general formula (III) or (III-1) and belonging to the genus Pseudomonas, Xontro-onas, Escherichia, Aeromonas, Achromobacter, Arthrobacter, Acetobacter, Alcaligenes, Kluyvera, Gluconobacter, Clostridium, Comamonas, Corynebacterium, Sarcina, Staphylococcus, Spirillum, Bacillus, Flavobacterium, Brevibacterium, Protaminobacter, Beneckea, Micrococcus, Proteus, Nycopiana or Rhodopseudomonas, (2) a culture broth of the microorganism, (3) a treated matter of the culture broth or (4) an enzyme produced by the microorganism. So far, enzymatic acylation of naturally occuring ss-lactam compounds such as 6-aminopenicillanic acid which is the ring of penicillins, 7-aminocephalosporanic acid and 7-aminodeacetoxycephalosporanic acid which are the ring of cephalosporins is reported numerously. However no example of enzymatic acylation of a S-lactam compound synthetically prepared such as the present compound having carbacephem ring has been reported. The finding that such miroorganism has an ability of absolute optically selective acylation of a carbacephem compound synthetically prepared is quite new. Compound [III3 used in the present invention is produced according to the method described in Japanese Published Unexamined Patent Application No. 128591/79 (German Offenlegungsschrift 2911786) and Japanese Patent Application No. 162008/7 a. A method of producing unpublished Compound IIII] is described in detail in Reference Example below. Compound [III-1] is produced according to the method described in Japanese Patent Application No. 14533/79 and 146488/79. A method of producing Compound [III-1] is described in detail in Reference Example below. As the reactive derivative of Compound [V], a compound which gives Compounds [V] by the hydrolysis with a microorganism used in the present invention, a culture broth of the microorganism, a treated matter of the culture broth and/or an enzyme produced by the microorganism, such as an alkylester with methyl group, ethyl group, and the like, a thioethylester with thioglycollic acid is mentioned The optically selective acylation reaction of Compound [III) with Compound (V) and the acylation reaction of Compound [III-1J with Compound [V) are carried out in the presence of an enzyme obtained from a microorganism capable of producing optically active Compound [I] or [ by optically selective acylation of optically inactive Compound [III] or optical acti-e Compound [IIIv As the microorganism having an ability of such acylation reaction or optically selective acylation reaction, such microorganism having an ability of producing optically active Compound [IV) or Compound [IV-1] from Compound [V) or a reactive derivative thereof and Compound [III) or Compound [III-1] and belonging to the genus Aeromonas, Achromobacter, Arthrobacter, Acetobacter, Alcaligenes, Escherichia, Xanthomonas, Kluyvera, Gluconobacter, Clostridium, Comamonas, Corynebacterium, Sarcina, Staphylococcus, Spirillum, Bacillus, Pseudomonas, Flavobacterium, Brevibacterium, Protaminobacter, Proteus, Beneckea, Micrococcus, Mycoplana and Rhodopseudomonas are used. The following strains are examples of the microorganism. Aeromonas hydrophila IFO 12634 Achromobacter aceris IFO 3320 Arthrobacter simplex ATCC 15799 Acetobacter aurantius IFO 3245 Acetobacter sp. ATCC 21760 Alcaligenes faecalis ATCC 8750 Escherichia coli ATCC 11105 Escherichia coli ATCC 13281 Xanthomonas citri IFO 3835 Xanthomonas physalidicola IFO 13555 Kluyvera citrophila ATCC 21285 Gluconobacter liquefaciens ATCC 14835 Gluconobacter dioxyacetonicus IFO 3271 Clostridium acetobutylicum IFO 3346 Comamonas terrigena IFO 12685 Corynebacterium tritici IFO 1216 Sarcina lutea 0 ATCC 9341 Staphylococcus aureus IFO 3060 Spirillum metamorphum IFO 12012 Bacillus megaterium ATCC 14945 Pseudomonas melanogenum ATCC 17808 Pseudomonas aeruginosa IFO 3451 Flavobacterimm SD. ATCC 21429 Brevibacterium cerinum ATCC 15112 Protaminobacter alboflavus IFO 13221 Proteus rettgeri ATCC 9250 Beneckea hyperoptica ATCC 15803 Micrococcus luteus AHU 1427 Mycoplana bullata IFO 13267 P'hodopseudomonas spheroides ATCC 21286 For carrying out the optically selective acylation reaction, the enzyme may be provided, more specifically, in any of the following forms: 1. As the culture liquor of the microorganism or treated matter thereof; 2. As cell bodies recovered from the culture broth by centrifugation which may be washed with saline water (usually about 1%), buffer solution and the like, or as a cell suspension; 3. As a disrupted cell suspension, i.e., a suspension of the cell bodies disrupted mechanically or. chemically; 4. As a cell free extract, i.e., a liquid obtained by removing the disrupted cell bodies from the disrupted cell suspension; or 5. As a purified enzyme solution which is obtained by recovering the enzyme protein with ammonium sulfate from the cell ree extract and subjecting the enzyme protein to gel iltration, ion-exchange cellulose column chromatography, ion-exchange sephadex column chromato graphy, and the like. Cells or the purified enzyme immobilized by a conventional method may be used. The reaction is carried out at a temperature of O to 500C, preferably 15 to 350C and at a pH of 5 to 8 in an inactive solvent which does not affect the reaction. As the solvent, water is most preferably used. Organic solvents such as acetone, methanol, ethanol, N,N- dimethylformamide, dimethylsulfoxide, and the like may be used alone or in combination with water.. It is effective to add phosphate buffer, Veronal buffer or citric acid buffer to control the pH in the reaction. Reaction time being influenced by the kind and concentration of enzymes, the kind and concentration of substrates, reaction temera- ture or reaction pH, is generally 30 minutes to 24 hours. It is most preferable to terminate the reaction when the reaction ratio reaches maximum.- The concentration of cells is preferably 1 to 50 mg by dry weight per 1 ml of the reaction solution. When a purified enzyme is using, it is appropriate to use the amount of the enzyme having the same activity as that of the dry cell. The substrate Compound [V .] is used in an amount of 0.5 to 50 mg per 1 ml of the reaction solution. Compound ±1111 is used in an amount of 0.1 to 50 mg per 1 ml of the' reaction solution. When enzymes preventing the reaction such as 6- lactamase, esterase, and the like are contained in the cell body, a mutant strain having a reduced productivity of' 'the enzyme may be used. Further, inhibitors against such enzymes may be added in the reaction system to raise the reaction ratio. After the completion of the reaction, isolation of the desired compound is carried out by a conventional method employed in the isolation and purification of organic compounds from culture liquors such as absorption using various carriers, ion-exchange chromatography, gel filtration, liquid-liquid extraction, and the like. The invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, Compound [I] or a pharmaceutically acceptable salt thereof in association with a pharmaceutical carrier or diluent. The compounds of this invention are administered by parenteral (intramuscular, intraperitoneal, intravenous, or subcutaneous injection routes), oral or rectal route of administration and can be formulated in dosage forms appropriate for each route of administration. Preparations according to this invention for parenteral administration include sterile aqueous or nonaqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid co=positions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. Compositions for oral administration may be presented in a form suitable for absorption by the gastrointestinal tract. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for examples, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for examples, lactose, sugar, maizestarch, calcium phosphate, sorbitol or glycine; lubricants for example, magnesium stearate, talc, polyethylene glycol, silica; disintegrants, for example, potato stardh or acceptable wetting agent such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the arts. Oral liquid preparations may be in the form of aqueous or oily suspension, solution, emulsions, syrups, etc. or may be presented as a dry product, for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additive such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose sugar syrup, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, emulsifying agents, forxamp1e, lecithin or sorbitan monooleate; non-aq;ueous vehicles, which may include edible oils, for example, almond oil, coconut oil, propylene glycol, or ethyl alcohol; ; presenatives, for'example, methyl or propyl phydroxybenzoates or sorbic acid. Compositions for rectal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax. The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient shall be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, andon the duration of the treatment. Generally, dosage levels of between 5 to 350 mg/kg of body weight daily are administered to mammalian patients to achieve an antibiotic effect. The present invention is explained in Examples below. Example 1. Preparation of (+)-cis-7-[2-(2-amino-4-thiazolyl)-2 syn-methOxyiminOacetamido3-1-azabicyclof4,2,03oct-2-en-8-on-2- carboxylic acid [the optically active compound of the compound represented by the general formula.(I') wherein A3 is CH3, '1 is H, cis refers to the stereochemistry at the 6- and 7-positions and the same shall apply hereinafter) EMI22.1 In this Example, 131.3 mg (0.30 m mole) of 2-(2tritylamino-4-thiazolyl-2-syn-methoxyimino acetic acid is dissolved in 1 m of anhydrous dichloromethane.and to the solvent 4.1 l of trithylamine-is added at a temperature of -20 C. After adding 61.7 mg of phosphorus pentachloride, the mixture is stirred at a temperature of -20 C for 30 minutes. The reaction mixture is concentrated under reduced pressure and the residue is dissolved in 1 mt of anhydrous tetrahydrofuran to obtain an acid chloride solution. Separately, 40.2 mg (0.17 m mole) of the monohydrate of the hydrochloride of (+)-cis-7-amino-l-azabicyclo r4,2,0]oct-2-en-8-on-2-carboxylic acid obtained as in Reference Example 2 is dissolved in a mixture of 1 ml of tetrahydrofuran and 1 mQ of water and 116.2 l of triethyl amine is added thereto. With stirring under ice cooling, the acid chloride solution prepared above is added dropwise to the solution and the mixture is allowed to react for one hour. The reaction solution is adjusted to a pH of 2.0 with 5% hydrochloric acid and extracted three times with 10 mQ of ethyl acetate. The ethyl acetate layer is washed with 10 ml of saturated saline solution, dried with sodium bicarbonate, and concentrated under reduced pressure to obtain 93 mg of a crude acyl compound {the optically active compound of represented by the general formula (II) wherein A3 is CH3, R'1 is H and NH2 is replaced with rtj. The compound is dissolved in 10 mi of 50% acetic acid and the solution is stirred at a temperature of 50 C for 30 minutes. After cooling to room temperature and removing deposited white precipitates by filtration, the reaction solution is concentrated and the residue is dissolved in a small amount of dimethylsulfoxide. The solution is charged on a column packed with 10 mQ of HP-10. Elution is carried out with water to a mixture of water and methanol (1:2). Fractions showing an Rf value of 0.3 by silica gel thin layer chror.=tography [plate: Merck Art. 5719 (Product ofE. Merck & Co.), so vent : butanol : acetic acid : water = 4 : 1 : 1] are combined and concentrated under reduced pressure to obtain 13.5 mg (yield 22.4%) of white crystals of the desired compound. Properties of the compound are as follows. m.p. 1720C (decomposition) [&alpha;]D15 +32.6 (DMSO, c = 0.5) IR (KBr)#maxcm-1: 1765, 1660, 1630, 1545, PMR (DMSO-d6)#: 9.26(1H,d), 7.19(2H,s), 6.75(1H,s), 6.28(1H,t), 5.50(1H,d-d,J = 8.9, 4.7), 3.83(3H,s), 2.5-1.0 (4H,m) These values coincide well with those of the corresponding d±-compound. From the strong antimicrobial activity, absolute configuration of this compound is assumed to be (6R, 7S). Example 2. Preparation of (-)-cis-7ss-[2-(2-amino-4-thiazolyl)-2 syn-methoxyiminoacetamido]-4&alpha;-methyl-l-azabicyclo[4,2,0]oct- 2-en-8-on-2-carboxylic acid [the optically active compound of the compound represented by the general formula (I') wherein 3 and R 1 are CH33 EMI24.1 In this Example, 76 mg (0.17 m mole) of 2-(2tritylaminho-4-thiezolyl)-2-syn-methoxyimino acetic acid is dissolved in 1.52 mL of anhydrous dichloromethane and 17.3 mg (0.17 m mole) of triethylamine is added at a temperature of -15 C. After adding 35.7 mg (0.17 m mole) of phosphorus pentachloride, the mixture is stirred at a temperature of -150C for 30 minutes. The reaction mixture is concentrated under reduced pressure and the residue is dissolved in 2 ml of anhydrous tetrahydrofuran to obtain an acid chloride solution. Separately, 28 mg (0.10 m mole) of the dehydrate of the potassium salt of (-)-cis-7ss-amino-4&alpha;-methyl-l-azabicyclo [4,2,0loct-2-en-8-on-2-carboxylic acid obtained as in Reference Example 4 is suspended in a mixture of 1.5 mi of tetrahydrofuran and water (1:1) and 36.3 mg (0.36 m mole) of triethylamLne is added thereto to make a homogeneous solution. With stirring under ice cooling, the acid chloride solution is added dropwise to the solution and the mixture is allowed to react for 45 minutes. The reaction mixture is extracted 4 times with 3 ml of ethyl acetate and the ethyl acetate layer is washed with 5 m± of saturated saline solution. The washing is dried with sodium bicarbonate and concentrated under reduced pressure to obtain 107.1 mg of a crude acyl compound (the optically active compound of the compound represented by the general formula (I') wherein A3 and '1 atom of is replaced with Trt}. The compound is dissolved in 4.5 mQ of 50% acetic acid and the solution is stirred at a temperature of 50 to 550C for 5 minutes. The solution is cooled to room temperature and the deposited white precipitate is removed by filtration. The cake is washed with 2 ml of 50% acetic acid. - The filtrate and the washing are combines and concentrated under reduced pressure. The residue is dissolved in a small amount o dimethylsulfoxide and charged on a column packed with 10 m*Q of HP-10. Elution is carried out with a mixture of water and methanol (5:1 to 2:1). Fractions showing an Rf value of 0.54 by silica gel thin layer chromatography (the same condition hereinbefore is used) are combined and concentrated under reduced pressure to obtain 12.9 mg (yield 23.8t) of white crystals of the desired compound. -Properties of the compound are as follows. m.p. about 180 C (decomposition) [&alpha;]D15 -27 (DMSO, c = 0.5 ) IR(KBr)#maxcm-1: 1770, 1672, 1633, 1540 PMR(DMSO-d6)#: 9.26(1H,d,J = 8.3), 7.18(2H,s), 6.75(1H,s), 6.31(1H,d,J = 5.1), 5.51(1H,d-d,J = 8.3, 5.0), 3.83(3H,s), 1.67(2H,m), 1.07(3H,d,J = 7.3) These values coincide well with those of the corresponding di-compound. From the strong antimicrobial activity, absolute configuration of this compound is assumed to be (4S,6R,7S). Example 3 Preparation of (+)-cis-7-[(R)-2-phenyl-2 aminoacetamido]-l-azabicyclo[4,2,0]oct-2-en-8-on-2 carboxylic acid [referred to as Compound (A) hereinafter]: EMI26.1 3-1) Preparation of disrupted cell suspension a) Cultivation of a microorganism having an ability of optically selective acylation As a seed strain, Pseudomonas melanogenum ATCC 17808 [Biological properties are described in Journal of the Agricultural Chemical Society of Japan, 37, 71 (1963)1 is used. As a seed medium, an aqueous solution containing 1 % polypeptone, 1 % yeast extract, 0.5 z meat extract, 0.5% sodium glutanate and 0.25 % sodium chloride and adjusted at a pH of 7.0 with 5N-NaOH is used. One loopful seed strain is inoculated into 10 ml the seed medium in 50 ml of a large test tube and culturing is carried out at a temperature of 300C for 24 hours. The whole amount of the seed medium is put into 300 ml of the culture medium in 2 l of an Elrenmeyer flask and culturing is carried out with shaking at a temperature of 300C. The composition of the culture medium is the same as that of the seed medium. b) Preparation of cell suspension After culturing for 24 hours, cell bodies are recovered from the culture broth by centrifugation and washed 2 times with 50 ml of 0.9 % saline solution. The cells are suspended in a concentration of 40 mg/ml by dry weight in 1/30 M phosphate buffer. The suspension (10 ml) is put in 50 ml of a large test tube and subjected to ultrasonic disintegration at 200 W for 2 minutes to prepare a disrupted cell suspension. In the treatment, a ultrasonic disintegrator Model UR 200 P (product of Tomy Seiko Co., Ltd.) is used. 3-2) Preparation of substrate solution 120 mg of (#)-cis-7-amino-l-azabicyclo[4,2,0] oct-2-en-8-on-2-carboxylic acid obtained as in GO 2911786 and 500 ma of the hydrochloride of D-phenylglycinemethylester are added to 9 ml of 1/30 M potassium phosphate buffer (pH 6.5). 5N-KOH is added in small portions and the mixture is again adjusted to a pH of 6.5 to dissolve two starting compounds. Finally, deionized water is added to make 10 ml of a solution. 3-3) Enzyme reaction In this step, 10 ml of the disrupted cell suspension is added to 10 ml of the substrate solution and enzyme reaction is carried out at a temperature of 300C for 5 hours. The reaction is monitored by high speed liquid chromargraphy using TRI ROTAR (product of Nippon Bunko Co., Ltd.) and Prepack colurr Nucleosil 10C18 (product of Gaskuro Kogyo Co., Ltd.). Elution is carried out with 7 % methanol-C.2 KH2 PO4 solution. Reaction reaches maximum in 5 hours. 3-4) Isolation and purification ef the desired compound: After the completion of reaction, cell bodies are removed from the reaction solution by centrifugation The supernatant is concentrated under reduced pressure and charged on a column (1.6 cm width, 50 cm height) packed with 100 ml of Diaion HP - 10 (product of Mitsubishi Kasei Kogyo Co., Ltd.). After washing with 200 ml of deionized water, elution is carried out with 30 t aqueous methanol solution. The eluate is collected in 10 ml of fractions. Then, fraction Nos. 20 to 25 containing the desired compound are concentrated under reduced pressure to make 0.5 ml of a concentrate. The concentrate is charged on a column (1.6 cm width, 64.5 cm height) packed with 130 ml of Sephadex-LH20 (Pharmacia Fine Chemicals Inc.) and elution is carried out with a mixture of water and methanol (50 : 50 by volume, the same shall apply hereinafter). The eluate is collected in 5 ml of fractions. The desired compound is eluted in 60 ml to 80 ml of fractions. The fractions are concentrated under reduced pressure to remove methanol and the residue is lyophilized to obtain 81 mg of a white powder, Properties of the product are as follows. 22 [&alpha;]D.(H2O)(c = 0.5 ); @@@ IR(KBr)#maxcm-1 : 1760, 1690, 1640 PMR(D2O)#(ppm): 7.51(5H, s), 6.08(1H, t, J = 4.2Hz), 5.41(1H, d, J = 4.9Hz), 5.19(1H, s), 3.83(1H, octet, J = 8.6, 3.7, 4.9Hz), 2.28-1.01(4H, m) The values mentioned above coincide with those of the less polar isomer in Example 6 of GO 2911787. Based on the data above, the white powder is identified as the desired compound. From the strong antimicrobial activity, absolute configuration of this compound is assumed to be (6R,7S). Example 4 Preparation of (+)-cis-7B-j (R)-2-phenyl-2- aminoacetamido]-4&alpha;-methyl-l-azabicyclo[4,2,0]oct-2-en-8- on-2-carboxylic acid [referred to as Compound (B) hereinafter): EMI28.1 4-1) Preparation of cell suspension A cell suspension is prepared as in Example 3-1) except that as the seed strain Xanthomonas citri IFO 3835 [Biological properties are described in Bergey's Mannual of Determinative Bacteriology VI, P.156 (1948)] is used. 4-2) -Preperation of substrate solution 200 mg of the trifluoroacetate of (#)-cis-7ss- amino-4C-methyl-l-azabicyclo [4,2,0] oct-2-en-8-on-2carboxylic acid obtained as in GO 2911786 and 500 mg of the hydrochloride of D-phenylglycinemethylester are added.in 9 ml of 1/30 M potassium phosphate buffer (pH 6.5). 5N-KOH is added in small portions and the mixture is again adjusted to 2 pH of 6.5 to dissolve two starting compounds. Finally, deionized water is added to make 10 ml of a solution. 4-3) Enzyme reaction and 4-4). Isolation and Purification of the desired compound. In this step, 10 ml of the disrupted cell suspension is added to 10 ml of the substrate solution and enzyme reaction is carried out at a temperature of 300C for 4 hours. The reaction is monitored as in Example 3. Reaction reaches maximum in 4 hours. Then, the same procedure as in Example 3-4) is repeated to obtain 76 mg of a white powder. Properties of the product are as follows. [&alpha;]D15 (H2O, c = 0.52): +4.23 IR(KBr)#maxcm-1: 3420, 1760, 1695, 1633 PMR (D2O)#(ppm): 7.51(5H, s), 6.10(1H, d, J = 5.1Hz), 5.47(1H, d, J =4.7Hz), 5.19(1H, s), 3.89(1H, m), 2.45 (1H, m), 1.44 - 1.04(2H, m), 1.00(3H, d, J--7.4Hz) The values mentioned above coincide with those of the less polar isomer obtained in Example 12 of GO 2911787. Based on the data, the white powder is identified as the desired compound. From the strong antimicrobial activity, absolute configuration of this compound is !assumed to be (4S,6R,7S). Example 5 Preparation of Compound (A) (Alternative method). As the seed strain, Escherichia coli ATCC 11105 lBiological properties are described in Bergey's Manual of Determinative Bacteriology VIII P.295 (1974)]. The same procedure as in Example 3 is repeated except that enzyme reaction is carried out for 12 hours to obtain 39 mg of a white powder. Properties of the product coincide well with those of the compound obtained in Example 3. Example 6 Preparation of (+)-cis-7-[(R)-2-p-hydroxyphenyl 2-aminoacetamido]-l-azabicyclo[4,2,0]oct-2-en-8-on-2carboxylic acid: EMI30.1 6-1) Preparation o cell suspension a) Cultivation of a microorganism having an ability of optically selective acylation. The sane procedure as in Example 3-1) a' is repeated except that as the seed strain, Kluyuera citrophila ATCC 21285 [Biological properties are described in J. General Applied Microbiology 3, 28-31 (1957)3 is used. b) Preparation oz cell suspension After culturing for 24 hours, cell bodies are recovered from the culture broth by centrifugation and washed 2 times with 50 ml of 0.9 % saline soltuion. The cells are suspended in a concentration of 40 mg/ml by dry weight in 1/30 M phosphate buffer. 6-2) Preparation of substrate solution 120 mg of (+ )-cis-7-amino-l-azabicyclo [4,2,0] Oct-2-en-8-on-2-carboxylic acid obtained as in GO 2911786 and 500 mg of the hydrochloride of D-p-hydroxyphenylglycinemethylester are added in 9 ml of 1/30 M potassium phosphate buffer (pH 6.5). 5N-KOH is added in small portions and the mixture is again adjusted to a pH of 6.5 to dissolve two starting compounds. Finally, deionized water is added to make 10 ml of a solution. 6-3) Enzyme reaction and 6-4) Isolation and Purification of the desired compound. In this 'step, 10 ml of the cell suspension is added to 10 ml of the substrate solution and enzyme reaction is carried out at a temperature of 300C for 20 hours. The reaction is monitored as in Example 3. Reaction reaches maximum in 20 hours. The same procedure as in Example 3-4) is repeated to obtain 65 mg of a white powder. Properties of the product are as follows. 200 [&alpha;]D =+107.5 (c = 0.5, 1M phosphate butter (pH 7.0)] IR(KBr)#maxcm-1: 3450, 3290, 3090, 1760, 1700(sh), 1685 PMR(D2O)#(ppm): 7.36(2H, d, J = 8.8Hz), 6.95(2H, d, J = 8.8z), 6.06(1H, t, J=3.9Hz), 5.40(111, d, J = r 8.8z), 6.06(1H, t, J=3.9Hz), 5.40(1H, d J= J= 4.6Hz), 5.12(1H, s), 3.84(1H, m), 2.22(2H, m), 1.62(1H, m), 1.12(1H, m) Based on the data mentioned above, the white powder is identified as te desired compound. From the strong antimicrobial activity, absolute configuration of this cpmpound is assumed to be (6R, 75). Example 7 Preparation of (+)-cis-7ss-[(R)-2-p-hydroxy phenyl-2-aminoacetamido]-4&alpha;-methyl-l-azabicyclo[4,2,0]oct- 2-en-8-on-2-carboxylic acid: EMI32.1 7-1) Preparation of cell suspension A cell suspension is prepared as in Example 6 except that as the seed strain Xanthomonas citri IFO 3835 is used. 7-2) Preparation of substrate solution A substrate solution is prepared as in Example 4-2). 7-3) Enzyme reaction and 7-4) Isolation and Purification of the desired compound: The same procedures as in Example 3-3) and 3-4) are repeated usin the cell suspension and the substrate solution prepared above to obtain 75 mg of a white powder. The reaction is carried out for 3 hours. Properties of the product are as follows [&alpha;]D20 = +12.8 [c = 0.5 , 1M phosphate buffer (ph 7.0)] IR(KBr)#maxcm-1: 3420, 3260, 1760, 1685. PMR(D2O)(ppm): 7.35(2H, d, J=8.OHz), 6.96(2H', d, J = 8.0Hz), 6.10(1H, d, J = 5.1Hz), 5.45(1H, d, J = 4.9Hz), 5.11(1H, s), 3.92(1H, m), 2.45(1H,m), 1.50-1.08(2H, m), 1.01(3H, d, J =7.1Hz) Based on the data mentioned above, the white powder is identified as the desired compound. From the strong antimicrobial activity, absolute configuration of this compound is assumed to be (4S, 6R, 7S). Example 8 Preparation of Compound (A) (Alternative method). The same procedure as in Example 3 is repeated except that 120 mg of (+)-cis-7-amino-l-azabicyclo[4,2,0]oct-2-en-8on-2-carboxylic acid obtained in Reference Example 2 is used in place of (+) cis-7-amino-1-azabicyclo [4,2,0] oct-2-en8-on-2-carboxylic acid to obtain 160 mg of a white powder. Properties of the product coincide with those of the-compound obtained as in Example 3. Example 9 Preparation of Compound (B) (Alternative method) The same procedure as in Example 4 is repeated except that 150 mg of (-)-cis-7ss-amino-4 -methyl-1-azabicyclo[4,2,01 oct-2-en-8-on-2-cnrboxylic acid obtained in Reference Example 4 is used in place of the trifluoroacetate (#)-cis-7ss-amino- 4&alpha;-methyl-l-azabicyclo[4,2,0]oct-2-en-8-on-2-carbonylic acid to obtain 150 mg of a white powder. Properties of the product coincide with those of the compound obtained in Example 4. Example 10 Antibacterial activities of the compounds obtained in Examples 3, 4, 6 and 7 are illustrated in Table 1. The compounds obtained in Reference Example below and cefazolin are used as controls. Heart Infusion Agar Dilution Method (pH 7.2) is used. In Table 1, numbers of the compound represent the following compounds and the letters A to O represent the following strains. 1. (+) compound obtained in Example 3, 2. (+) compound obtained in Example 6 of GO 2911787 3, (-) compound obtained in Example 6 of GO 2911787. 4. (+) compound obtained in Example 4. 5. (+) compound obtained in Example 12 of GO 2911787.. 6. (-) compound obtained in Example 12 of GO 2911787. 7. (+) compound obtained in Example 6. 8. (+) compound obtained in Example 47 of GO 2911787. 9. (+) con pound obtained in Example 7. 10. (+) compound obtained in Example 44 of GO 2911787. 11. Cefazolin (control). MIC of the (+) compounds obtained in Examples 6 and 12 of GO 2911787 coincide with MIC of the f compounds obtained in Examples 3 and 4. A. Staphylococcus aureus 209-P B. Staphylococcus aureus Smith C. Staphylococcus epidermidis D. Escherichia coli NIHJC-2 E. Escherichia coli Juhl F Klebsiella pneumoniae 8045 G. Klebsiella pneumoniae Y-60 H. Serratia marcescens T-26 I. Serratia marcescens T-55 J. Proteus mirabilis 1287 K. Proteus vulgaris 6897 L. Proteus morganii KY 4298 M. Proteus rettgeri KY 4289 N. Pseudomonas aeruginosa 145 O. Pseudomonas putida F264 Table 1 EMI35.1 <tb> I <SEP> \COmPOUnd <tb> 1 <SEP> 1 <SEP> 2 <SEP> 3 <SEP> 4 <SEP> 5 <SEP> 6 <SEP> 7 <SEP> 8 <SEP> 9 <SEP> 10 <SEP> 11 <tb> <SEP> Strain <SEP> \ <SEP> ¯ <SEP> . <tb> <SEP> A <SEP> 0.4 <SEP> 0. <SEP> - <SEP> 0.78 <SEP> 0.78 <SEP> - <SEP> 0.4 <SEP> 1.56 <SEP> 0.4 <SEP> 0,4 <SEP> C0,05 <tb> <SEP> B <SEP> 6.25 <SEP> 12.5 <SEP> - <SEP> 6.25 <SEP> 6.25 <SEP> - <SEP> 3.12 <SEP> 12.5 <SEP> 1.56 <SEP> 1.56 <SEP> 0.4 <tb> <SEP> C <SEP> '- <SEP> 3.12 <SEP> 6.25 <SEP> - <SEP> ' <SEP> 3.12 <SEP> 6.25 <SEP> - <SEP> 1.56 <SEP> 6.25 <SEP> 0.78-1.56 <SEP> 0.78 <tb> <SEP> D <SEP> 3.12 <SEP> 12.5 <SEP> 50 <SEP> 12.5 <SEP> 12.5 <SEP> 50 <SEP> 3.12 <SEP> 12.5 <SEP> 6.25 <SEP> 6.25 <SEP> 1.56 <tb> <SEP> E <SEP> 3.12 <SEP> 12.5 <SEP> 100 <SEP> 12.5 <SEP> 12.5 <SEP> 100 <SEP> 6.25 <SEP> 12.5 <SEP> 6.25 <SEP> 6.25 <SEP> 1.56 <tb> <SEP> F <SEP> 0.78 <SEP> 3.12 <SEP> 5b <SEP> 0.78 <SEP> 3.12 <SEP> 50 <SEP> 0.78 <SEP> 3.12 <SEP> 3.12 <SEP> 12.5 <SEP> 0.78 <tb> <SEP> G <SEP> 3.12 <SEP> 12.5 <SEP> 50 <SEP> 25 <SEP> > 100 <SEP> 50 <SEP> 3.12 <SEP> 12.5 <SEP> 100 <SEP> > 100 <SEP> 3.12 <tb> <SEP> H <SEP> - <SEP> - <SEP> > 100 <SEP> - <SEP> > 50 <SEP> > 100 <SEP> - <SEP> 100 <SEP> - <SEP> 50 <SEP> 100 <SEP> > 100 <tb> <SEP> I <SEP> 12.5 <SEP> 25 <SEP> 100 <SEP> 25 <SEP> > 100 <SEP> 100 <SEP> 6.25 <SEP> 50 <SEP> 12.5 <SEP> 50 <SEP> 50 <tb> <SEP> J <SEP> 12.5 <SEP> 25 <SEP> 25 <SEP> 25 <SEP> 50 <SEP> 25 <SEP> 50 <SEP> 50 <SEP> 25 <SEP> 50 <SEP> 12.5 <tb> <SEP> 50 <SEP> 25 <SEP> 25 <SEP> 25 <SEP> 50 <SEP> 25 <SEP> 100 <SEP> - <SEP> 100 <SEP> > 100 <SEP> 12.5 <tb> <SEP> L <SEP> 50 <SEP> 100 <SEP> 50 <SEP> 25 <SEP> 100 <SEP> 50 <SEP> 100 <SEP> - <SEP> 100 <SEP> > 100 <SEP> > 100 <tb> <SEP> N <SEP> 12.5 <SEP> 50 <SEP> 6.25 <SEP> 12.5 <SEP> > 100 <SEP> 12,5 <SEP> 25 <SEP> - <SEP> - <SEP> 25 <tb> <SEP> N <SEP> - <SEP> > 100 <SEP> - <SEP> > 50 <SEP> > 100 <SEP> - <SEP> - <SEP> > 100 <SEP> - <SEP> - <SEP> - <SEP> > 100 <SEP> <tb> <SEP> 0 <SEP> 100 <SEP> > 100 <SEP> - <SEP> > 50 <SEP> 100 <SEP> - <SEP> 100 <SEP> - <SEP> 50 <SEP> 100 <SEP> > 100 <tb> Example 11 Preparation of t-butyl ester of (+)-cis-7-(2 phenyl-2-t-butyloxycarbonyl-aminoacetamido) -3-chloro-1- azabiyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid EMI36.1 In this example, 150 mg (0.55 mmole) of (#)-cis- 7-amino-3-chloro-2-t-buthyloxycarbonyl-l-azabicyclo[4,2,0] oct-2-en-8-one is dissolved' in 3 ml of anhydrous methylene chloride. 165 m (0.66 mmole) of (R)-N-t-butyloxycarbonyl phenylglycine is dissolved in 5 m± of anhydrous tetrahydrofuran and the solution is cooled to -15 to -10 C. 0.66 ml (0.66 nmole) of 1N-N-methylmorpholine-tetrahydro furan and 0.66 ml (0.66 nmole) of 1N-iBu chloroformatetetrahydrofuran are added dropwise and the mixture is stirred at the same temperature for 20 minutes. The above-prepared amine solution is added dropwise to the mixture wilile maintaining the same temperature and temperature of the mixture is raised to room temperature gradually. The mixture is stirred at room temperature overnight. 10 mQ of methylene chloride is added to the reaction mixture and the mixture is washed with 10 % citric acid, saturated aqueous sodium bicarbonate and saturated aqueous sodium chloride in this order and dried with anhydrous sodium sulfate. The mixture is concentrated under reduced pressure and purified by silica gel chromatography (silica gel; 20 g of C-200 produced.by Wako Junyaku. Co., Ltd., Japan, solvent; ethyl acetate : n-hexane = 1 : 5 by volume, this is same hereinafter) to obtain 124-mg (yield 44.6%) of the desired compound (mixture of the diasteroisomers) having the following properties. -: : 1780, 1730, 1680, 1655, 1550 max NMR(CDCl3)#(ppm): 7.34(5/2H, s), 7.31(5/2H, s), 6.93(1h, m), 5.63(1H, m), 5.30 (l/2H,dd, J¯5.4, 6.8 Hz), 5.11-5.22(3/2H, m), 3.76-3.91 (1H, m), 2.33-2.66(2H, m), 1.52(9H, s), 1.41(9H, s), 0.92 1.97(2H, m) Example 12 Preparation of (6R,7S) 7-(R)-phenylglycinamido- 3-chloro-l-azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid (C) and (6S,7R) 7-(R)-phenylglycinamido-3-chloro-lazabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid (D) EMI37.1 In this example, 1 ml of methylene chloride and 1 mQ of trifluoroacetic acid are added to 128.4 mg (0.25 nmole) of t-butyl ester of (#)-cis-7-(2-phenyl-2-t-butyloxy carbonylaminoacetamido)-3-chloro-l-azabicyclo[4,2,0]oct-2 en-8-on-2-carboxylic acid under ice cooling. and the mixture is stirred at the same temperature for 1.5 hours. The solvent is distilled off and the resultant oily material is subjected to high speed liquid chromatography column: Microbondapak C-18 (product of Waters Co.), solvent: 7t methanol and 0.2N KH2PO4] to separate diastereoisomers. Each separated eluate fraction is concentrated under reduced pressure and desalted using 10 mQ of Diaion HP-10 resin (solvent; methanol : water = 1 : 1) to obtain 9.4 mg of more polar isomer (D) and 7.6 mg of less polar isomer (C) (total yield 19.1%). More polar isomer (D! [&alpha;]D21 : -75.8 (c = 0.4, H2O) Melting point: 3000C or more (browning) IR(KBr)#maxcm-1: 1765, 1700, 1550 NMR (D2O)#(ppm): 7.49(5H, s), 5.16(1H, d, J = 4.7Hz), 5.05(1H, s), 3.78-4.03(1H, m), 2.53-2.67(2H, m), 1.26-2.09(2H, m) Less polar isomer (C) [&alpha;]D21 : +34.0 ( c = 0.35, H2O) Melting point: 300 CC or more (browning) IR(KBr)#maxcm-1: 1770, 1700, 1620 NMR (D2O)#(ppm): 7.51(5H, S), 5.36(1H, d, J = 4.6Hz), 5.19(1H, s), 3.83-4.00(1H, m), 2.41-2.56(2H, m), 1.49-1.76(1H, m), 1.14-1.45(1H, m) As described below, the less polar isomer (C)' exhibits a greater antimicrobial activity and is assumed as the (6R, 75) absolute configuration. Example 13 Preparation of (#)-cis-7-phenylacetammido-3-chloro- l-azabicyclot4,2,0]oct-2-en-8-on-2-carboxylic acid: EMI39.1 In this example, 150 mg (0.45 mmole) of trifluoroacetate of (t) -cis-7-amino-3-chloro-l-azabicyclo[4,2,0]oct- 2-en-8-on-2-carboxylic acid is suspended in a mixed solvent of 2 ml of water and 2 mi of acetone, 134 mg (1.5 mmole) of sodium bicarbonate is added thereto to make a homogenous solution. To the solution is added dropwise a solution of 84.2 mg (0.54 nmole) of phenylacetyl chloride in 0.5 ml of acetone under ice cooling in one hour. The mixture is stirred for 3 hours, adjusteed to pH 2 with 1N hydrochloric acid and extracted 5 tines with each 2 ml of ethyl acetate. The extract is concentrated under reduced pressure and the residue is cried to obtain 80 mg (55.0%) of the desired compound. TR(XBr)vCm : 1790, 1705, 1630, 1560 NMR(CD3OD)#(ppm): 7.29(5H,s), 5,#.36(1H, d, J=5 Hz), 3.79-399(1H, m), 2.56-2.75(2H, m), 1.17-2.02(2H, m) Example 14 Preparation of (6R,7S)7-(R)-p-hydroxyphenylglucinamido-3-chloro-l-azabicyclo[4,2,0]oct-2-en-8-on-2carboxylic acid: : EMI39.2 In this example, 1 mA of methylene chloride and 1 mt of trifluoroacetic acid are added under ice cooling to 104.3 mg (20 nmole) of t-butyl ester of (#)-cis-7-[2- (p-hydroxyphenyl)-2-t-butyloxycarbonylaminoacetamido]-3chloro-l-azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid fixture of the diasterecisomers) synthesized from t-butyi ester of (#)-cis-7-amino-3-chloro-l-azabicyclo[4,2,0]oct- 2-en-8-on-2-carboxylic acid and N-t-butyloxycarbonyl- (R) -p- hydroxyphenylglycine. The mixture is stirred at the temperature for 1.5 hours and concentrated under reduced pressure. The resultant oily material is subjected to high speed liquid chromatography column: Microbondapak C-18, solvent : 7%-methanol-0.2N potassium dihydrogen phosphate) to separate the diastereoiosmers. Fractions containing the less polar isomer are concentrated under reduced pressure and desalted by 10 mA of HP-10 resin (solvent, methanol h water = 1 : 1) to obtain 10.5 mg (28.7%) of the desired compound. [&alpha;]D20 : +44 ( c = 0.25, 1M phosphate buffer, pH 7.0 IR(KBr)#maxcm-1: 1765, 1695, 1615, 1520 NMR (D2O)#(ppm): 7.36(2H, d, J = 8.8 Hz), 6.96(2H, d, J = 8.8 Hz), 5.36(1H, d, J = 4.6 Hz), 5.11(1H, s), 3.81-4.00(1H, m), 2.42-2.58(2H, m), 1.59-1.77(1H, m), 1.17-1.48(1H, m) Antibacterial activity of the compounds obtained in Examples 12 and 14 is shown in the following table. The activity is determined by the Heart Infusion Agar Dilution Method (pH 7.2). Cephalexin and cefazolin are used as reference. From the antimicrobial activity, absolute configuration of this compound is assumed to be (6R,TS). Table 2 EMI41.1 <tb> <SEP> Microorganism <SEP> MIC( g/ml) <tb> <SEP> a <SEP> b <SEP> c <SEP> d <tb> Staphylococcus <SEP> aureus <SEP> 209-p <SEP> 0.10.40.2 <SEP> < 0.05 <tb> Staphylococcus <SEP> aureus <SEP> Smith <SEP> 1.56 <SEP> 1.56 <SEP> 3.12 <SEP> 0.4 <tb> Staphylococcus <SEP> epidermis <SEP> 1.56 <SEP> 1.56 <SEP> 3.12 <SEP> 0.78 <tb> Escherichia <SEP> coli <SEP> NIHJC-2 <SEP> 1.56 <SEP> 1,56 <SEP> 12.5 <SEP> 1.56 <tb> Escherichia <SEP> coli <SEP> Juhl <SEP> ' <SEP> 1.56 <SEP> 1.56 <SEP> 12.5 <SEP> 1.56 <tb> Xlebsiella <SEP> pneumoniae <SEP> 8045 <SEP> 0.2 <SEP> 0.78 <SEP> 3.12 <SEP> 0.78 <tb> Klebsiella <SEP> penumoniae <SEP> Y-60 <SEP> 6.25 <SEP> 12.5 <SEP> 50 <SEP> 3.12 <tb> Serratia <SEP> marcescens <SEP> T-55 <SEP> 6.25 <SEP> 6.25 <SEP> 50 <SEP> 50 <tb> Proteus-mirabilis <SEP> 1287 <SEP> 3.12 <SEP> 3.12 <SEP> 25 <SEP> 12.5 <tb> Proteus <SEP> vulgaris <SEP> 6897 <SEP> 100 <SEP> 100 <SEP> 25 <SEP> 12.5 <tb> Proteus <SEP> organic <SEP> KY4298 <SEP> > 100 <SEP> > 100 <SEP> > 100 <SEP> > 100 <tb> Pseudomonas <SEP> putida <SEP> F264 <SEP> 100 <SEP> .100. <SEP> > 100 <SEP> > 100 <tb> Proteus <SEP> rettgeri <SEP> KY4298 <SEP> 100 <SEP> 100 <SEP> < 100 <SEP> 25 <tb> a: The compound (C) obtained in Example 12 b: The compound obtained in Example 14 c: Cephalexin d: Cefazolin Example 15 Preparation of Compound (A) (Alternative method): 15-1) Cultivation of microorganisms As the seed strain, the following strains are used. Aeromonas hydrophila IFO 12634 Achromobacter aceris IFO 3320 Arthrobacter simplex ATCC 15799 Acetobacter aurantius IFO 3245 Acetobacter sp. ATCC 21760 Alcaligenes faecalis ATCC 8750 Escherichia coli ATCC 13281 Xanthomonas physalidicola IFO 13555 Gluconobacter liquefaciens ATCC 14835 Gluconobacter dioxyacetonicus IFO 3271 Comamonas terrigena IFO 12685 Corynebacterium tritici IFO 1216 Sarcina lutea ATCC 9341 Staphylococcus aureus IFO 3060 Spirillum methamorphum IFO 12012 Bacillus megaterium ATCC 14945 Pseudomonas aeruglnosa IFO 3451 Flavobacterium st ATCC 21429 Brevibacterium cerium ATCC 15112 Protaminobacter alboflavus IFO 13221 Proteus rettgeri ATCC 9250 Beneckea hyperotica ATCC 15803 Micrococcus luteus AHU 1427 Mycoplana bullata IFO 13267 Mycoplana dimorpha IFO 13213 Rhodopseudomonas spheroides ATCC 21286 As a medium, an aqueous solution containing 1% meat extract, 1% peptone, 0 3% sodium chloride, 0.5% yeast extract and adjusted at a pH of 7.2 with SN-NaOH is used. One loopful seed strain is inoculated into 300 mQ of an Erlenmeyer flask containing 30 mQ of the medium and culturing is carried out with shaking at a temperature of 30 C for 24 Irours, Cell bodies are recovered from the culture broth by filtration and washed with 5 mA of 0.98 sodium chloride solution. The cells are again recovered by centrifugation and suspended in a concentration of 40 mg/ml by dry weight in 1/30M phosphate buffer (pH 6.5). 15-2) Preparation of substrate solution A substrate solution is obtained as in Example 3-2). That is, 123 mg of (#)-cis-7-amino-l-azabicyclo[4,2,0]oct-2- en-8-on-2-carboxylic acid and 400 mg-of the hydrochloride of D-phenylglycinemethylester are added in 15 mQ of 1/30M phosphate buffer ( 6.5). 5N-KOH is added in small portions and the mixture is adjusted to a.ptI of 6.5.to dissolve the two starting compounds. Finally, deionized water is added to make 20 ml of a solution. 15-3) enzyme reaction The sama procedure as in Example 6 is carried out using 0.5 mQ of the cell suspension obtained in 15-1) and 0.5 mQ of the substrate solution. The reaction is carried out at a temperature of 30 C for 24 hours 15-4) Identification of the desired compound Reaction is monitored by high speed liquid chromatography in the same manner as in Example 1. As apparent from Table 3, the desired more polar diastereoisomer, i.e. (-)-cis-7-[(R)-2-phenyl-2-aminoacetamido]l-azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid '[GO 29117873 is not formed at all and only the desired less polar isomer, i.e. (+)-cis-7-[(R)=-2-phenyl-2-aminoacetamido]-lazabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid is formed. The enzyme produced by all strains in Table 3 have an ability of optically selective acylation of cephalosporin analogs. Table 3 The amount of Microorganism Compound (A) produced (mg) Aeromonas hydrophila IFO 12634 0.05 Achromobacter aceris IFO 3320 0.08 Arthrobacter simplex ATCC 15799 0.06 Acetobacter aurantius IFO 3245 0.04 Acetobacter sp. ATCC 21760 1.02 Alcaligenes faecalis ATCC 8750 0.04 Escherichia coli ATCC 13281 . 0.25 Xanthomonas physalidicola IFO 13555 0.95 Gluconobacter liquefaciens ATCC 14835 0.13 Gluconobacter dioxyacetonicus IFO 3271 0.20 Comamonas terrigena IFO 12685 0.03 Corynebacterium tritici IFO 1216 0.07 Sarcina lutea ATCC 9341 0.05 Staphylococcus aureus IFO 3060 0.09 Spirillum methamorphum IFO 12012 0.18 Bacillus megaterium ATCC 14945 0.05 Pseudomonas aeruginosa IFO 3451 0.03 Flavobacterium s7. ATCC 21429 0.04 Brevibacterium cerinum ATCC 15112 0.20 Protaminobacter alboflavus IFO 13221 1.21 Proteus rettgeri ATCC 9250 0.09 Beneckea hyperoptica ATCC 15803 0.68 Micrococcus luteus AHU 1427 0.22 Mycoplana bullata IFO 13267 0,55 Mycoplana dimorpha IFO 13213 0.98 Rhodopseudomonas spheroidas ATCC 21286 0.11 * 2.66 mg of the compound is produced in the yield of 100%. - Example 1E Preparation of Compound (A) (Alternative method): In this Example, Clostridium acetobutylicum IFO 3346 is inoculated in 100 mQ of Potato Dextrose Broth (product of DIFCO Lab.). The fermentor is sealed after the air is substituted with sterilized nitrogen and culturing is carried out at a temperature of 300C for 48 hours. Cell bodies are recovered and washed with physiological saline solution. The cell is suspended in 2 mS of 1/30M potassium phosphate buffer (pH 6.5). The same reaction as in Example 15 is repeated to obtain 0.12 mg of Compound (A). Example 17 Preparation of (6R, 7s)7-(R)-phenylglycinamido- 3-chloro-1-2z2bicycloL4,2,0]oct-2-en-8-on-2-carboxylic acid (alternative method): EMI45.1 17-1) Preparation of cell suspension a) Cultivation of a microorganism having an ability of optically select acylation. As a seed strain, Pseudomonas melanogenum ATCC 17808 tBiological properties are described in Journal of the Agricultural Chemical Society of Japan 37, 71(1963)3 is used. As the seed medium, an aqueous solution containing 1% polypeptone, 1% yeast extract, 0.5% meat extract, 0.5% sodium glutamate and 0.25% sodium chloride and adjusted at a pH of 7.0 with SN-NaOH is used. One loopful seed strain is inoculated into 10 mL the seed medium in 50 mQ of a large test tube and culturing is carried out at-a temperature of 300C for 24 hours. The whole amount of the seed medium is put into 300 mQ of the culture medium in 2 Q of Erlenmeyer flask and culturing is carried out at a temperature of 300C. The composition of the culture medium is the same as that of the seed medium. b) Preparation of cell suspension After culturing for 24 hours, cell bodies are recovered from the culture broth by centrifugation and washed 2 times with 50 mQ of 0.9% saline solution. The cells are suspended in a concentration of 20 mg/ml by dry weight in 1/30M phosphatebuffer (pH 6.5). 17-2) Preparation of a substrate solution 200 mg of the trifluoroacetate of (+)-cis-7-amino-3-chloro-l-azabicyclo 14,2,0]oct-2-en-8-on-2-carboxyliç acid (starting compound -a) obtained as in Reference Example 8 and 800 mg of the hydro- chloride of 9-phenylglycine methylester (starting compound b) are added in 9 ml of 1/30M potassium phosphate buffer (pH 6.5). 5N-SOH is added in a small portion and the mixture is again adjusted to a pE of 6.5 to dissolve two starting compounds. Finally, deionized water is added to make 10 mt of a solution. 17-3) Enzyme reaction - In this step, 10 ml of the disrupted cell suspension is added to 10 mQ of the substrate solution and enzyme reac tion is carried out at a temperature of 30 C for 1.5 hours; The reaction is monitored by. high speed liquid chromatography using TRI ROTAR and Prepack column Nucleosil 10C18. Elution is carried out with 7% methanol-0.2M KH2P04 solution. Reaction reaches maximum in a yield of 90% to the starting compound a in 1.5 hours. 17-4) Isolation and purification of the desired compound: After the completion of reaction, cell bodies are removed from the reaction solution by centrifugation. The supernatant is concentrated under reduced pressure and charged on a column (1.6 cm width, 50 cm height) packed with Diaion HP-10. After adding 200 mQ of deionized water, elution is carried out with 25% aqueous methanol solution. Then, the fractions containing the desired compound are concentrated under reduced pressure to make a 5 mi of concentrate The concentrate is charged on 2 column (1.6 cm width, 64.5 cm height) packed with 130 m of Sephadex-LH20 and elution is carried out with a solvent of water and methanol (50 : 50). The desired compound is eluted in 55 mt to 75 mi of fractions. The fractions are concentrated under reduced pressure and lyophilized to obtain 78 mg of a white powder. Properties of the product coincide with the less polar isomer (C) in Example 12. Antibacterial activities of the compound obtained in Example 17 are shown in Table 2 as compound (a) Heart Infusion Agar Dilution Method (pH 7.2) is used. Cefazolin is used as a control. From the antimicrobial activity, absolute configuration of this compound is assumed to be (6R, 7S). Example 18 Preparation of (6R, 7S) 7-[(R)-2-p-hydroxyphenyl 2-aminoacetamido-3-chloro-l-azabicyclo[4,2,0]oct-2-en-8-on 2-carboxyliW id: EMI48.1 18-1) Preparation of cell suspension Cultivation of a microorganism The same procedure as in Example 17-l)is repeated except that as the seed strain, Xanthomonas citri IFO 3835 lBiological properties are described in Bergey's Manual of Determinative Bacteriology VI p.156 (1948)1 is used. 18-2) Preparation of substrate solution 200 mg of the trifluoroacetate of (+)-cis-7ss-amino- 3-chloro-l-azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid obtained as in Ref erence Example 8 and 800 mg of the hydrochloride of D-p-hydro.':yphenylglycine methylester are added in 9 ml of 1/30M potassium phosphatebuffer (pH 6.5). 5N-KOH is added in small portions and the mixture is again adjusted to a pH of 6.5 to dissolve the starting compounds. Finally, deionized water is added to make 10ml of a solution. 18-3) Enzyme reaction and 18-4) Isolation and purification of the desired compound After the completion of the reaction, cells are removed by centrifugation and the resulting filtrate is concentrated under reduced pressure. The concentrate is charged on a column (1.6 cm width, 50 cm height) packed with 100 mQ of Diaion HP-20AG (100 to 200 mesh, product of Mitsubishi Kasei Kogyo Co., Ltd.). Then 150 mQ of water and 150 ml of 108 aqueous methanol are passed through the column and elution is carried out with 20% aqueous methanol. Fractions (210 to 750 ml) of eluted 20% aqueous methanol are combined and concentrated under reduced pressure. The concentrate is charged on a column (0.88 cm width, 70 cm height) .packed with 43 ml of Sephadex LH20 and elution is carried out with a mixture of water and methanol(1 : 1, by volume). Fractions (28 to 34 ml) are combined and concentrated under reduced pressure- to remove methanol. The resulting residue is lyophilized to obtain 47 mg of a white powder. The product is identified as the desired compound based on the following properties. [&alpha;]D20 = +44.0 [ c = 0.25 , 1M phosphate buffer (pH 7.0)] IR#maxKBr (cm-1): 1765, 1695, 1615 NMR(100M, D20-DSS)6: 7.36(2H, d, J=8.8 Hz), 6.96(2H, d, J=8.8 Hz), 5.36(1H, d, J=4.6 Hz), 5.11(1H, s); 3.81-4.00 (1H, m), 2.42-2.58(2H, m), 1.59-1.77(1H, m), 1.17-1.48 (lH, m) Antimicrobial activity of the compound obtained in this example is shown in Table 2 as compound (b). Example 19 Preparation of (6R,7S) 7-(R)-2-phenylglycinamido3-chloro-lazabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid (Alternative method): : EMI50.1 19-1) Preparation of cell suspension a) Cultivation of a microorganism having an ability of optically selective acylation As a seed strain, Pseudomonas melanogenum ATCC 17808 [Biological properties are described in Journal of the Agricultural Chemical Society of Japan, 37, 71 (1963)3 is used. As a seed medium, an aqueous solution containing 1% polypeptone, 18 yeas extract, 0.5% mat extract, 0.5% sodium glutamate and 0.25% sodium chloride and adjusted at a pH of 7.0 with 5N-NaOi is used. One loopful seed strain is inoculated into 10 mQ the seed medium in 50 mQ of a large test tube and culturing is carried out at a temperature of 300C for 24 hours. The whole amount of the seed medium is put into 300 m2 of the culture medium in 2 Q of an Erlenmeyer flask and culturing is carried out with shaking at a temperature of 30 C. The composition of the culture medium is the same as that of the seed medium. b) Preparation o cell suspension After culturing for 24 hours, cell bodies are recovered from the culture broth by centrifugation and washed 2 times with 50 mZ of 0.9t saline solution. The concentrate is charged on a column (1.6 cm width, 64.5 cm height) packed with 130 mQ pf Sephadex-LH2O. (Pharmacia and elution is carried out with a mixture of water and methanol (50 : 50). The desired compound is eluted in 55 ml to 75 mQ of fractions. The fractions are concentrated under reduced pressure and the residue is lyophilized to obtain 12.8 mg of a white powder. Properties of the product coincide with those of the product obtained in Example 17. The cells are suspended in a concentration of 20 mg/ml by dry weight in 1/30M phosphate buffer (pH 6.5). 19-2) Preparation of substrate solution 100 mg of (-)-cis-7-amino-3-chloro-l-azabicyclo- [4,2,0]oct-2-en-8-on-carboxylic acid (Starting compound a) obtained as in Reference Example 9 and 800 mg of the hydrochloride of D-phenylglycine methylester are added in 9 ml of 1/30N potassium phosphate buffer (pH 6.5). 5N-XOH is added in small portions and the mixture is again adjusted to a pH of 6.5 to dissolve two starting compounds. Finally, deionized water is added to make 10 mZ of a solution. 19-3) Enzyme reaction In this step, 10 ml of the cell suspension is added to 10 m of the substrate solution and enzyme reaction is carried out at a temperature of 300C for 1.5 hours. The reaction is monitored by high speed liquid chromatography using TRIROTAR and Prepack column Nucleosil lOC18, Elution is carried cut with 7% methanol-0.2M SH2PO4- solution. Reaction reaches maximum in 1.5 hours. Yield to the starting compound- (a) is 90%. 19-4) Isolation and purification of the desired compound After the completion of reaction, cell bodies are removed from the reaction solution by centrifugation, The supernatan. is concentrated under reduced pressure and charged on a column (1.6 cm width, 50 cm height) packed with 100 mQ of Diaion HP-10. After adding 200 mZ of deionized water, elution is carried out with 25% aqueous methanol solution. The fractions containing the desired compound are concentrated under reduced pressure to make 5 mQ of a concentrate. The concentrate is charged on a column (1.6 cm width, 64.5 cm height) packed with 130 mQ of Sephadex LH 20 (product cf Pharmacia Fine'Chemicals Inc.) and elution is carried out with a mixture of water and methanol (50 : 50). The desired compound is eluted in fractions of 55 mt to 75 mt. The fractions are concentrated under reduced pressure and lyophilized to obtain 128 mg of a white powder. Properties of the product coincide with those of the product obtained in Example 17. Example 20 Preparation of (6R, (S)7-[(R)-2-phenyl-2-amino- acetamido]-3-chloro-l-azabicyclo[4,2,0]oct-2-en-8-on-2carboxylic acid (Alternative method): Example 17-1) is repeated except that as the seed strain Kluyvera citro?hira ATCC 21285 [Biological properties are described in J. General Applied Microbiology 3, 27-31 (1957)1 is used. After 24 hours of the main cultivation, cells are recovered from the culture broth by centrifugation and a cell suspension is obtained as in the same treatment as Example17-1). Preparation of a substrate solution and enzyme reaction are carried out in the same manner as in Example 17-2) and 17-3),respectively, except that reaction is carried out for 20 hours. Purification is carried out by column chromatography using HP-10 and Sephadex tH20 as in Example 17-4). Fractions containing the desired compound are lyophilized to obtain 86 mg of a white powder. Properties of the product coincide with those of the compound in Example 17. Reference Example 1 Antimicrobial activities of the compounds obtained in Examples 1 and 2 are as follows. Heart Infusion Agar Dilution method (pH 7.2) is used. The cephalosporin compound having the same acyl side chain corresponding to the di- compound is used as a control. A : The compound obtained in Example 1 A': The dQ-compound corresponding to the compound obtained in Example 1 B : The compound obtained in Example 2 B': The dQ-compound corresponding to the compound obtained in Example 2 C : Cephalosporin compound represented by the following formula. EMI53.1 Table 4 EMI54.1 Microorganism <SEP> MIC <SEP> ( g/ml) <tb> <SEP> A <SEP> A' <SEP> B <SEP> B' <SEP> C <tb> Staphylococcus <SEP> aureus <SEP> 209-p <SEP> 3.12 <SEP> 12.5 <SEP> 1.56 <SEP> 6.25 <SEP> 0.78 <tb> Staphylococcus <SEP> aureue <SEP> Smith <SEP> 6.25 <SEP> 25 <SEP> 6.25 <SEP> 12.5 <SEP> 1.56 <tb> Staphylococcus <SEP> epidermis <SEP> 12.5 <SEP> 25 <SEP> 3.12 <SEP> 12.5 <SEP> 1.56 <tb> Escherichia <SEP> coli <SEP> NIHJC-2 <SEP> 0.02 <SEP> 0.05 <SEP> 0.02 <SEP> 0.05 <SEP> 0.1 <tb> Escherichia <SEP> coli <SEP> GN2411-5 <SEP> 0.01 <SEP> 0.05 <SEP> #0.01 <SEP> 0.02 <SEP> 0.05 <tb> Escherichia <SEP> coli <SEP> Juhl <SEP> 0.02 <SEP> 0.1 <SEP> 0.02 <SEP> 0.05 <SEP> 0.05 <tb> Klebsiella <SEP> pneumoniae <SEP> 8045 <SEP> #0.006 <SEP> #0.006 <SEP> #0.01 <SEP> 0.01 <SEP> #0.01 <tb> Klebsiella <SEP> pneumoniae <SEP> Y-60 <SEP> 0.02 <SEP> 0.05 <SEP> 0.02 <SEP> 0.05 <SEP> 0.05 <tb> Serratia <SEP> marcescens <SEP> T-26 <SEP> 0.2 <SEP> 0.78 <SEP> 0.4 <SEP> 0.78 <SEP> 0.78 <tb> Serratia <SEP> marcescens <SEP> T-55 <SEP> 0.02 <SEP> 0.1 <SEP> 0.05 <SEP> 0.2 <SEP> 0.1 <tb> Proteus <SEP> mirabilis <SEP> 1287 <SEP> 0.01 <SEP> 0.02 <SEP> #0.01 <SEP> 0.01 <SEP> 0.02 <tb> Proteus <SEP> vulgaris <SEP> 6897 <SEP> #0.006 <SEP> 0.01 <SEP> #0.01 <SEP> 0.01 <SEP> #0.01 <tb> Proteus <SEP> morganii <SEP> KY <SEP> 4298 <SEP> 0.05 <SEP> 0.1 <SEP> 0.02 <SEP> 0.1 <SEP> 0.05 <tb> Proteus <SEP> rettgeri <SEP> KY <SEP> 4289 <SEP> #0.006 <SEP> #0.006 <SEP> #0.01 <SEP> 0.01 <SEP> #0.01 <tb> Pseudomonas <SEP> aeruginosa <SEP> #1 <SEP> 6.25 <SEP> 25 <SEP> 25 <SEP> 50 <SEP> 6.25 <tb> Pseudomonas <SEP> aeruginosa <SEP> 145 <SEP> 50 <SEP> 50 <SEP> 100 <SEP> > 100 <SEP> 50 <tb> Pseudomonas <SEP> putida <SEP> 264 <SEP> 0.1 <SEP> 0.4 <SEP> 0.05 <SEP> 0.05 <SEP> 0.1 <tb> Reference Example 2 Preparation of (+) -cis-7-amino-l-azabicyzlo4,2,0 oct-2-en-8-on-2-carboxylic acid: 2-1) Preparation of disrupted cell suspension 1) Cultivation of a microorganism having an ability of optical selective deacylation As the seed strain, Kluyvera citrophila ATCC 21285 [Biological properties are described in J. General Applied Microbiology 3, 28-31 (1957)] is used. As the seed medium, an aqueous solution containing 1% polypeptone, 1$ yeast extract, O.S% meat extract, 0.5% sodium glutamate and 0.25% sodium chloride and adjusted at a pH of 7.0 with 5N-NaOH is used. One loopful of the seed strain is inoculated into 10 mQ of the seed medium in 50 mQ of a large test tube and culturing is carried out at a temperature of 300C for 24 hours The whole of the seed broth is inoculated into 300 mQ of the culture medium in 2 l of an Erlenmeyer flask and culturing is carried out at a temperature of 30 C with shaking. The composition of the culture medium is the same as that of the seed medium. 2) Preparation of disrupted cell suspension After culturing for 24 hours, the culture broth is subjected to centrifulgation to obtain cell bodies. The cells are washed twice with 50 ml of 0.9% saline solution and suspended in a concentration of 40 mg/ml by dry weight in 1/30M phosphate buffer solution. Then, 10 m± of the cell suspension is put in 50 mQ of a large test tube and subjected to ultrasonic disintegration at 200 W for 2 minutes to obtain disrupted cell suspension. In the treatment, ultrasonic disintegrator Model URZOOP (product of Tomy Seiko Co., Ltd.) is used. 2-2) Preparation of a substrate solution In this step, 200 mg of (#9-cis-7-phenylacetamid- l-azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid obtained as in GO 2911787 is added into 9 mQ of 1/30 phosphate buffer (pH 6.5). Since the compound'is not dissolved. 2N NaOH is added in a small portion and the mixture is again adjusted at a pH of 6.5 to dissolve the compound. Finally, deionized water is added to make 10 mQ of a solution 2-3) Enzyme reaction In this step, 10 ml of the disrupted cell suspension mentioned above is added in 10 mt of the substrate solution and enzyme reaction is carried out at a temperature of 30 C for 80 minutes. Time course of the reaction is illustrated in Table 5. Table 5 The amount of Reaction period Compound (111-1) Yield (minutes) produced (mg/ml) (Mol ratio, %) 10 2.0 33 20 2.6 43 40 2.9 48 60 3.0 50 80 3.0 oSO As apparent from the Table 5, the reaction and yield are stationary since the conversion ratio of the mixture of the optically active isomers reaches 50% (mol ratio). 2-4) Isolation and Purification of the desired compound After the completion of the reaction, cells are removed by centrifugation from the reaction solution; The supernatant is adjusted at a pH of 3.0 with 2N-hydrochloric acid and charged on a column (2.6 cm width, 51 cm height) packed with 270 me of Diaion HP-10, Elution is carried out with deionized water and the eluate is collected in 5 mi of fractions. The desired compound is eluted from 280 mL to 315 ml of the fractions. The fractions are concentrated under reduced pressure, lyophilized and dissolved in a small amount of a mixture of water and methanol (50 : 50 by volume, the same shall apply hereinafter). The solution is charged on a column (1.6 cm width, 64.5 cm height) packed with 130 me of Sephadex LH.20 (Farmacia Fine Chemicals Inc.). Elution is carried out with a mixture of water and methanol (50 : 50). The eluate is collected in 5 ml of fraction. Fractions from 65 mQ to 85 ml are combined and concentrated under reduced pressure to remove methanol. Then, the residue is lyophilized to obtain 48 mg of a white powder. Properties of the product are as follows. cm-1 IR(KBr)Vrnax : 18DO, 1790, 1775, 1640, 1620 NMR(100M D2O-DSS)#: 6.46(1H, dd, J = 3.5, 4.7 Hz), 4.88(1H, d, J = 5.2Hz), 4.06(1H, m), 2.5-1.5 (4H,m) It is revealed that the compound has one mole of hydrochloric acid and water. The properties of the compound coincide well with those of the corresponding dQ-compound. The value of optical rotation is [&alpha;] D15 z +48 [c=0 .5, in 1 phosphate buffer solution (pH 7.0)] which coincides well with the value in Reference Example 3 below, [&alpha;]D15 =48.5 [c=0.5, in IM phosphate buffer solution (pH 7.0)). The compound shows a ninhydrin positive single spot at an Rf value of 0.22 on silica gel thin layer chromatography [thin layer plate Merck Art 5721 (product of E. Merck & Co.), solvent for development, isopropanol : acetic acid : water = 4 : 1 : 1]. The Rf value coincides with that of the optically inactive d±-compound. Reference Example 3 Preparation of (+)-cis-7-amino-l-azabicyclo[4,2,0]oct 2-en-8-on-2-carboxylic acid (Alternative method) 3-1) Preparation of disrupted cell suspension The same procedure as in Reference Example 2-1) is repeated. 3-2) Preparation of a substrate solution In this step, 100 mg of.(+) -cis-7-l(R)-2-phenyl- 2-aminoacetamido]-l-azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid obtained as in GO 2911787 is dissolved in 5 mQ of 1/30M phosphate buffer solution (pH 6.5). 3-3) Enzyme reaction In this step, 5 mQ of the disrupted cell suspension mentioned above is added in 5 mQ of the substrate solution and enzyme reaction is carried out at 300C for 24 hours. 3-4) Isolation and Purification In this step, 46 mg of a white powder is obtained by a similar method as in Reference Example 2-4). Properties of the compound coincide well with those of the compound obtained in Reference Example a a]l5 = 48.50 [c=0.5, in 1M phosphate buffer solution (pH 7.0)] Reference example 4 Preparation of (-)-cis-7ss-amino-4&alpha;-methyl-l- azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid: 4-1) Preparation of disrupted cell suspension A similar procedure as in Reference Example 2-1) is repeated. 4-2) Preparation of a substrate solution A similar procedure as in Reference Example 2-2) is repeated except that (+)-cis-78-phenylacetamid-4a-mcthyl- l-azabicyclo [4,2,0] oct-2-en-8-on-2-carboxylic acid obtained as in GO 2911787 is used. 4-3) Enzyme Reaction A similar procedure as in Reference Example 2-3) is repeated except that the disrupted cell suspension and the substrate solution obtained in 4-1) and 4-2) are used. Reaction ratio becomes stationary in one hour. The reaction is continued for 120 minutes. The yield is 508 (mol ratio) of the mixture of optically active compounds, 4-4) Isolation and purification of the desired compound An almost similar procedure as in Reference Example 2-4) is repeated. After the completion of reaction, cells are removed by centrifugation from the reaction solution. The supernatant is charged on a column (2.5 cm width, 46 cm high) packed with 220 mQ of Diaion HP-10. Elution is carried the out with deionized water andReluate is collected in 5 mZ of fractions. The desired compound is eluted in 200 mQ to 270 mQ of fractions. The fractions are concentrated under reduced pressure, lyophilized, and dissolved in a small amount of water and methanol (50 : 50). The solution is charged on a column (1.6 cm width, 64.5 cm hight packed with 130 ml of Sephadex LH-20 and elution is carried out with a mixture of water and methanol (50 : 50). The eluate is collected in 5 ml of fractions. The fractions from 65 my to 80 mQ are combined and concentrated to remove methanol. Then, the residue is lyophilized to obtain 30.5 mg of a white powder. Properties of the compound are as follows. IR(KBr) #maxcm-1: 1800 (sh), 1760 (sh), 1740, 1680, 1630 NMR(100M D2O-DSS)#: 6.16 (1H, d, J = 5.1 Hz), 4.52 (1H, d, J = 4.9 Hz), 3.86 (1H, m), 2.64 (1H, m), 1.9-1.4 (2H, m), 1.10 (3H, d, J = 7.3 Hz) It is revealed that the compound is a potassium salt having 2 moles of water. The properties above coincide well with those of the corresponding dQ compound. The compound shows a ninhydrin positive single spot at Rf = 0.33 on a silica gel thin layer chromatography (the same silica gel as in Example 1 is used). The Rf value coincides with that of the optically inactive dl-compound. Optical rotation [&alpha;]D15 = -30 (c=0.5, in 1M phosphate buffer solution). The value coincides well 'with that in Reference Example 4, [&alpha;]D15 = -30.8 [c=0.5, in 1M phosphate buffer solution (pH 7.0)]. Reference Example 5. Preparation of (-) -cis-7ss-amino-4&alpha;-methyl-1-azabicyclo [4,2,0]oct-2-en-8-on-2-carboxylic acid (Alternative method) 5-1) Preparation of disrupted cell Suspension. A similar procedure as in Reference Example 4-1) is repeated. 5-2) Preparation of a substrate solution In this step, 100 mg of (+)--cis--7B-[(R) -2-phenyl- 2-aminoacetamido]-4&alpha;-methyl-1-azabicyclo[4,2,0]oct-2-en-8- on-2-carboxyli acid obtained as in GO 2911787 is dissolved in 5 mQ of 1/30M phosphate buffer solution. 5-3) Enzyme reaction In this step, 5 m± of the disrupted cell suspension described above is added in 5 mQ of the substrate solution and enzyme reaction is carried out at a temperature of 300C for 24 hours. 5-4) Isolation and Puficiation of the desired product A similar procedure as in Reference Example 4-4) is repeated to obtain 55 mg of a white powder. Properties of the compound coincide well with those in Reference Example 4. Optical rotation [aJ15 = -30.8 [c=0.5, in 1M phosphate buffer solution (pH 7.0)]. Reference Example 6 Preparation of (l)-cis-7-azido-3-chloro-2-t- butyloxycarbonyl-1-azabicyclo[4,2,0]oct-2-en-8-one: EMI61.1 The present compound is prepared according to the following processes a),b), c) and d). 6-a) Preparation of (#)-cis-7-azido-3-phenylthio l-azabicyclof4,2,030ctane-8-on-2-carboxylic acid, t-butylester EMI61.2 In this Example, 528 mg (2 m mole) of (*)-cis-7- azido-1-azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid, t-butylester prepared as in the method described in Japanese Published Unexamined Patent Application No, 128591/79 is dissolved in 15 m of anhydrous benzene and 0.2 ml (2 m mole) of thiophenol and 0.2 mQ (2 m mole) of piperidine are added. The mixture is stirred at room temperature for 2 hours. After the completion of reaction, the reaction solution is washed with 10% citric acid and saturated saline solution and dried with anhydrous sodium sulfate. The solvent is removed by distillation under reduced pressure and the obtained oily residue is purified by silica gel column chromatography using 30 g of silica gel and a solvent of ethyl acetate and n-hexane (1 : 4) to obtain 720 mg (96.3%) of the desired compound. Melting point: 77.5-78.0 C KBr (cm-1). 2110 1765 1745 max NMR (CDCl3)#: 7.28-7.60 (5H, m), 4.78 (1H, d, J = 5 Hz), 4.33 (1H, s), 3.78-3.98 (1H, m), 3.81 (1H, s), 1.50-2.34 (4H, m), 1.42 (9H, s) 6-b) Preparation of (#)-cis-7-azido-3-phenyl- sulfinyl-l-azabicyclol4,2,0]octane-8-on-2-carboxylic acid, t-butylester: EMI62.1 In this Example, 480 mg (1.28 m mole) of 3-phenylthio compound obtained as in Reference Example 6-a) is dissolved in 50 mA of anhydrous chloroform and 240 mg (1.41 m mole) of m-chloroperbenzoic acid under ice cooling. The mixture is allowed to react with stirring under ice cooling for 30 minutes. The reaction mixture is washed with saturated sodium bicarbonate' and saturated sodium chloride and dried with anhydrous sodium sulfate. The solvent is removed by distillation under reduced pressure to obtain 500 mg (99.9%) of the desired compound. Melting point: 95.5-96.50C IR#maxKBr (cm-1): 2120, 2100, 1780, 1735, 1035 NMR (CDCl3)#: 7.55-7.91 (5H, m), 4.87(1H, d, J = 4.6 Hz), 4.05(1H, s), 3.90-4.10(1H, m), 3.10(1H, s), 1.70-2.84 (4H, m), 1.30 (9H, s) Preparation of (i)-cis-7-azido-3-chloro-3- phenylsulfinyl-1-azabicyclo[4,2,09octane-8-on-2-carboxylic acid, t-butylester: EMI63.1 In this Example, 109 mg of sulfoxide compound obtained as in Reference Example 6-b) is dissolved in 1 mQ of anhydrous methylene chlorIde and 23.5 mg (0.42 m mole) of calcium oxide is added. After adding 27 l (0.34 m mole) of sulfinyl chloride, the mixture is allowed to react with stirring under ice cooling for one hour. The reaction mixture is washed with 10% citric acid, saturated sodium bicarbonate and saturated sodium chloride solution and dried with anhydrous sodium sulfate. The solvent is removed by distillation and the obtained oily residue is subjected to silica gel chromatography using 5 g of silica gel and a solvent of ethyl acetate and n-hexane (1 : 5) to obtain 66.5 mg (56.1%) of the purified desired oily compound. IR#CHCl3 (cm-1). 2120 1770 1735 1055 max NMR (CDCl3)#: 7.53-8.00(5H, m), 4.90 (1H, d, J = 5 Hz). 4.43 (1H, s), 4.15-4.35 (1H, m), 1.83-2.85 (4H, m), 1.38 (9H, s) 6-d) Preparation of (+)- F,is-7-azido-3-chloro-l- azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid, t-butylester: EMI64.1 In this Example, 1.3 g (3.06 m'mole) of 3-chloro-3phenylsulfinyl compound obtained as in Reference Example 6-c) is heated under reflux with 100 mQ of carbon tetrachloride for 6 hours. After the completion of reaction, the reaction solution is subjected to distillation under reduced pressure to remove the solvent. The obtained residue is subjected to purification by silica gel chromytography using 100 g of silica gel and a solvent of ethyl acetate and n-hexane (I : 5) to obtain 596 ing (65.2%) of the desired compound. Melting point: 96-97 C IR#KBR (cm-1). 2120 1765 1735 1630 max PMP (CDCl3)#: 4.93 (1H, d, J = 5 Hz), 3.72-3.92 (1H, m), 2.56-2.70 (2H, m), 1.86-2.32 (2H, m), 1.55 (9H, s) CMR (CDCl3)#: 127.7, 125.0 Reference Example 7 Preparation of (#)-cis-7-amino-3-chloro-1- azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid, t-butyl ester: EMI64.2 In this Example, 350 mg (1.17 m mole) of the azido compound obtained as in Reference Example 6 is dissolved in 20 mQ of ethanol and 1.2 mQ of lN-hydrochloric acid and 70 mg of 10% palladium-carbon. Hydrogen gas is passed through the mixture at room temperature and atmospheric pressure for 3 hours and palladium-carbon is removed by filtration. The filtrate is concentrated under reduced pressure to obtain a solid. The solid is dissolved in water and washed with ether. After adding sodium bicarbonate to make weakly alkaline, the water layer is extracted with ethyl acetate. The ethyl acetate layer is washed with saturated saline solution and dried with anhydrous sodium sulfate. The solvent is removed by distillation under reduced pressure to obtain 218.4 mg (68.4%) of a powder of the desired compound. Melting point: 102.5-104.50C IR#KBr(cm-1). 1770 1720 1620 max NMR CDCl3#: 4.43 (1H, d, J = 5 Hz), 3.52-3.90(1H, m), 2.52-2.72(2R, m), 2.22(2B, br), 1.87-2,17(2H, m), 1.55 (9H, s), Reference Example 8 Preparation of the trifluoroacetate of (+)-cis-7- amino-3-chloro-1-azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid: EMI65.1 In this Example, 102.2 mg (0.31 m mole) of the amino-ester compound obtained as in Reference Example 7 and 1 mQ of trifluoroacetic acid is added under ice cooling. The mixture is stirred at room temperature for 30 minutes. The solvent is removed by distillation under reduced pressure to obtain an oily residue. To the residue is added ether and the resulted powder is recovered by filtration. The powder is lyophilized to obtain 75.5 mg (60.92) of the desired compound. Melting point: 208-2200C (dec.) 1765, 1630 max Reference Example 9 Preparation of (-)--ci s-7-amino-3-chlaro-l-azabi- cyclo[4,2,09oct-2-en-8-on-2-carboxylic acid: 9-1. Preparation of disrupted cell suspension 1) Cultivation of a microorganism having an ability of optically selective deacylation As the seed strain, Kluyvera citrophila ATCC 21285 [Biological properties are described in J. General Applied Microbiology 3, 28-31 (1957)] is used. As the seed medium, an aqueous solution containing 1% polypeptone, 1% yeast extract, 0.5% meat extract, 0.5% sodium glutamate and 0.25% sodium chloride and adjusted at a pH of 7.0 with 5N-NaOH is used. One loopful seed strain is inoculated into 10 mi of the seed medium in 50 ml of a large test tube and culturing is carried out at a temperature of 30 C for 24 hours. The whole of the seed broth is inoculated into 300 mi of the culture medium in 2 l of an Erlenmeyer flask and culturing is carried out at a temperature of 300C with shaking. The composition of the main culture medium is the same as that of the seed medium. 2) Preparation of disrupted cell suspension After culturing for 24 hours, the culture broth is subjected to centrifugation to obtain cell bodies. The cells are washed twice with 50 mQ of 0. 9% saline solution and suspended in a concentration of 40 mg/mi by dry weight in 1/30M phosphate buffer solution (pH 8.0). Preparation of a substrate solution In this step, 200 mg of (+)- cis-7-phenylacetamido- 3-chloro-1-azabicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid obtained as in Example 13 is added into 9 mt of 1/30M phosphate buffer (pH 8.0). Since the compound is . not dissolved, 2N-NaOH is added in a small portion and the mixture is again adjusted to a pH of 8.0 to dissolve the compound. Finally, deionized water is added to make 10 ml of a solution. 9-3. Enzyme reaction In this step, 10 mQ of the disrupted cell. suspension mentioned above is added in 10 ml of the substrate solution and enzyme reaction is carried out at a temperature of 400C for 80 minutes. Time course of the reaction is illustrated in Table 6 Table 6 The amount of Reaction period Compound III-l) Yield (minutes) produced tmg/mQ) (Mol ratio, %) 10 1.3 20 20 1.8 28 40 2.0 31 60 2.3 36 80 2.4 37 9-4. Isolation and Purification of the desired compound After the completion of the reaction, cells are removed by centrifugation from the reaction solution. The supernatant is concentrated'under reduced pressure to make 5 mQ of solution. The solution is charged on a column (1.75 cm width, 42 cm height) packed with Diaion HP-10. Elution is carried out with deionized water. The desired compound is eluted from 90 mQ to 120 mQ of -the fractions. The fractions are concentrated under reduced pressure, to make 2 mt of solution and the solution is adjusted to pH 3.5 with IN-hydrochloric acid to deposit crystals The crystals are recovered by filtration, washed with a small amount of methanol and dried to obtain 38 mg of. a white powder. Properties of the product are as follows. IR(KBr)#maxcm-1: 3200, 1800, 1790 (sh), 1640 (sh), 1630, 1555 N.IR (lOOM D2O-DSS)#: 4.47(lH, d, J = 5.1 Hz), 3.8(lR, m), 2.64 (2H, m,), 1.93 (2H, m) Optical rotation [&alpha;]D25 = - 2.7 (c=0.24, 1M phosphate buffer, pH 7.0) Reference Example 10 Preparation of (-)-78-amino-4o-methyl-a-zabicyclo [4,2,0] oct-2-en-8-on-2-carboxylic acid: 10-1) Preparation of disrupted cell suspension A similar procedure as in Reference Example 2-1) is repeated. 10-2) Preparation of a substrate solution A similar procedure as in Reference Example 2-2) is repeated except that (#)-cis-7ss-phenylacetamido-4&alpha;-methyl- l-azabicyclo [4,2,0) oct-2-en-8-on-2-carboxylic acid obtained as in GO 2911787 is used. 10-3) Enzyme reaction A similar procedure as in Reference Example 2-3) is repeated except that the disrupted cell suspension and the substrate solution obtained in 10-1) and 10-2) are used. Reaction ratio becomes stationary in one hour. The reaction is continued for 120 minutes. The yield is 50 % (mol ratio) of the mixture of optically active compounds. 10-4) Isolation and purification of the desired compound An almost similar procedure as in Reference Example 2-4) is repeated. After the completion of reaction, cells are removed by centrifugation from the reaction solution. The supernatant is charged on a column (2.5 cm width, 46 cm height) packed with 220 ml of Diaion H-10. Elution is carried out with deionized water and the eluate is collected in 5 ml of fractions. The desired compound is eluted in 200 ml to 270 ml of fractions. The fractions are concen trated under reduced pressure, lyophilized, and dissolved in a small amount of water and methanol (50 : 50). The solution is charged on a column (1.6 cm width, 64,5 cm height) packed with 130 ml of Sephadex LH-20 and elution is carried out with a mixture of water and methanol (50 : 50). The eluate is collected in 5 ml of fractions. The fractions from 65 ml to 80 ml are combined and concentrated to remove methanol. Then, the residue is lyophilized to obtain 30.5 mg of a white powder. Properties of the compound are as follows. IR(KBr)#cm-1 max : 1800, 1770(sh), l760(sh) 1740, 1680, 1630 NMR (100M D2O-DSS)#: 6.16 (1H, d, J = 5.1 Hz), 4.52 (1H, d, J = 4.9 Hz), 3.86 (1H, m), 2.64 (1H, m), 1.9-1.4 (2H, m), 1.10 (3H, d, J = 7.3 Hz) It is revealed that the compound is a potassium salt having 2 moles of water. The properties above coincide 'well with those of the corresponding dl-compound. The compound shows a ninhydrin positive single spot at Rf = 0.33 on a silica gel thin layer chromatography (the same silica gel as in Reference Example 2-4) is used). The Rf value coincides with that of the optically inactive dl-compound. Optical rotation [&alpha;]D15 = -30 (c=0.5, in 1M phos phate bhuffer solution). The value coincides well with that in Reference Example 11, 150 = -30.8 [c=0.5, in 1M phosphate buffer solution (pH 7.0)]. Reference Example 11 Preparation of Preparation of (-)-7ss-amino-4&alpha;-methyl-1-azabicyclo (-) 7B-amino-4a-ethyl-r-azabicyclo [4,2,0] oct-2-en-8-on-2-carboxvlic acid (Alternative method). 11-1) Preparation of disrupted cell suspension A similar procedure as in Reference Example 10-1) is repeated. 11-2) Preparation of a substrate solution 100 mg of (#)-cis-7ss-[(R)-2-phenyl-2-aminoacetamido]- 4&alpha;-methyl-1-azabicyclo [4,2,0] oct-2-en-8-on-2-carboxylic acid obtained as in GO 2911787 is dissolved in 5 m9 of 1/30M phosphate buffer solution (pH 6.5). 11-3) Enzyme reaction As in Reference Example 2-3), 5 ml of the disrupted cell suspension described above is added in 5 ml of the substrate solution and enzyme reaction is carried out at a temperature of 300C for 24 hours 11-4) Isolation and Purification of the desired product A similar procedure as in Reference Example 10-4) is repeated to obtain 55 mg of a white powder. Properties of the compound coincide well with those in Reference Example 10. 150 Optical rotation [a) D ¯ -30.8 [c=0.5, in 1M phosphate buffer solution (pH 7.0))

Claims: What is claimed is: (1) Optically active acylated cephalosporin analogs represented by the general formula (I) EMI71.1 wherein R1 represents a hydrogen or a lower alkyl group, R2 represents a hydrogen or a halogen atom, R3 represents a hydrogen or a protective group of carboxylic acid, X represents an acyl group represented by the formula X CO wherein X1 represents the following two groups: : 1) a group represented by the general formula EMI71.2 wherein B represents an unsaturated six membered carbocycle which is selected from cyclohexenyl group, cyclohexadienyl group and phe?yl group or a five or six membered heterocycle, A1 represents substituent(s) which is selected from hydrogen atom, hydroxyl group, a lower alkoxy group having 1 to 4 carbon atoms, a halo group, nitro group, amino group, aminomethyl group, methylsulfonamide group and a lower acyloxy group r-v-ing 1 to 4 carbon atoms, n is a number from O to 5, and A2 represents amino group, hydroxyl group, carboxyl group or sulfo group), 2) a group represented by the general formula EMI71.3 [wherein A1, B and n have the samp significance as defined above and A3 represents hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, a lower alkenyl group having 2 to 6 carbon atoms, a lower alkinyl group having 2 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms or an aryl group, those groups being unsubstituted or substituted with suitable substituent(s) which is selected from carboxyl group, cyan9 group, a halo group, carbamoyl group and a lower alkyioxycarbonyl group having 1 to 4 carbon atomsl, and the hydrogens at the 6- and 7-positions have cis configuration and pharmaceutically acceptable salts thereof. (2) The compound according to claim 1 wherein A1 is an amino group, B is a five membered heterocycle, A3 is a lower alkyl group having 1 to 6 carbon atoms or substituted lower alkyl group having carboxyl group as substituent and 0A3 group has syn configurtion. (3) The compound according to claim 2 wherein R2 is a hydrogen, B is a 2-substituted thiazolyl group ,and A3 is a methyl group. (4) The compound according to claim 3 wherein R1 is a hydrogen. (5) The compound according to claim 4 wherein R3 is a hydrogen, that is, (+)-cis-7-[2-(2-amino-4-thiazolyl)-2-syn methoxyiminoacetamido]-1-azabicyclo [4,2,0] oct-2-en-8-on2-carboxylic acid. (6) The compound according to clain 3 wherein R1 is a methyl group. (7) The compound according to claim 6 wherein R3 is a hydrogen. (8) The compound according to claim 7 whe'reinfthe . methyl group at the 4-position has the same configuration as the hydrogens at the 6- and 7-positions, that is, (-)-cis-7 [2-(2-amino-@-thiazolyl)-2-syn-methoxyiminoacetamido]-4&alpha;- methyl-l-azabicyclo 14,2.0] oct-2-en-8-on-2-carboxylic acid. (9) The compound according to claim 1 wherein A1 is a hydrogen or hydroxy group, B is a phenyl group and A2 is an amino group. (10) The compound according to claim 9 wherein R1 and R3 are a hydrogen. (11) The compound according to claim 10 wherein R2 is a chlorine atom. (12) The compound according to claim 11 wherein A1 is a hydrogen atom and Aa is an amino group, that is, (6R, 7S3 7-(R)-phenylglycinamia"o-3-chloro-l-azabicyclo14,2,01oct- 2-en-8-on-2-carboxylic acid. (13) The compound according to claim 11 wherein A1 is p-hydroxy group and A2 is an amino group, that is, (6R, 7S) 7-(R)-p-hydroxyphenylglycinamido-3-chloro-1-azabicyclo [4,2,0) oct-2-en-8-on-2-carboxylic acid. (14) The compound according to claim 9 wherein R2 and R3 are - a hydrogen. (15) The compound according to claim 14 wherein R1 is a hydrogen or a methyl group. (16) The compound according to claim 15 wherein A1 is a hydrogen atom or p-hydroxy group and A2 is an amino group. (17) The compound according to claim 16 wherein R1 and A1 are hydrogen atoms, that is, (6R, 7S) 7-(R)-phenylglycinamido-l-azabicyclo L4,2,o3 oct-2-en-8-on-2-carbocylic acid. (18) The compound according to claim 16 wherein R1 is a hydrogen and A1 is a p-hydroxy group, that is, (6R, 7S) 7-(R)-p-hydroxypher.ylglycinamido-l-azabicyclo 04S2,o3 oct-2-en-8-on-2-carboxylic acid. (19) The compound according to claim 15 wherein R is a methyl group and A1 is a hydrogen atom, that is, (6R, 7S) 7-(R)-phenylglycinamido-4-methyl-1-azabicyclo ,2,oct-2-en-8-on-2-carboxylic acid. (20) The compound according to claim 15 wherein R1 is a methyl group and A1 is a p-hydroxy group, that Is, (6R, 7S) 7-(R)-p-hydroxyphenylglycinamido-4-methyl-1-aza bicyclo[4,2,0]oct-2-en-8-on-2-carboxylic acid. 21. A process for producing cephalosporin analogs represented by tne general formula (I): EMI74.1 [wherein X represents an acyl group represented by the general formula X1CO wherein X1 represents the following two groups: 1) a group represented by the general formula EMI74.2 [wherein B represents an unsaturated six menbcred carbocycle which is selected from cyclohexenyl group, cyclohexadienyl group and phenyl group or a five or six meniered heterncycle, At represents substituent(s) which is selected from hydrogen atom, hydroxyl group, a lower alkoxy group having I to 4 carbon atoms, a halo group, nitro group, amino group, aminomethyl group, methylsulfonamide group dnd a lower acyloxy group having 1 to 4 carbon atoms, n is a number from 0 to 5, and A2 represents amino group, hydroxyl group, carboxyl group cr sulfo group), 2) a group represented by the general -formula EMI75.1 (wherein A1, B snd n have.the same significance as defined above and A3 represents hydrogen atom, a lower alkyl group having I to 6 carbon atoms, a lower alkenyl group Eaving 2 .to 6 carbon atones, a lower alkinyl group having 2 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms or an aryl group, those groups being unsubstituted or substituted with a suitable substituent which is selected from carboxyl group, cyano group, a halo group, carbamoyl group and a lower alkyloxycarbonyl group having 1 to 4 carbon atoms, K1, R2 and R3 have the same meaning as defined above) and pharmaceutically acceptable salts thereof, which comprises acylating optically active cephalosporin analogs represented by the general formula (II): EMI75.2 (wherein R1, R and R3 have the same meaning as defined above) or a- functionally equivalent compound with carboxylic acid represented by the general formula (III) X2COOH (III) [wherein X2 represents the following two groups: 1') a group represented by the general formula: : EMI76.1 [wherein B and n have the same significance as defined above, A'1 represents a substituent which is selected from hydrogen atom, hydroxyl group, a protected hydroxyl group, a lower alkoxy group having 1 to 4 carbon atoms, á halo group, nitro group, a protected amino group, a protected aminomethyl group, methylsulfonamido group and a lower acyloxy group having 1 to 4 carbon atoms,' and A ' 2 represents a protected amino group, hydroxyl group, a protected hydroxyl group, carboxyl group, a protected carboxyl group, sulfo group or a protected sulfo group) 2') a group represented by the general formula: : EMI76.2 [wherein A'1, B and n have the same significance as defined above and A4 represents hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms, a lower alkenyl group having 2 to 6 carbon atoms, a lower alkinyl group having 2 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms or an aryl group, those groups being unsubstituted or substituted with a suitable substituent which is selected from a protected carboxyl group, cyano group, a halo group, carbamoyl group and a lower alkyloxycarbonyl group having 1 to 4 carbon ator's], or with reactive derivatives of the carboxylic acid and, thereafter, optionally deprotecting the protecting group in the group X2CO- and/or -COOR3 and, optionally, converting to pharmaceutically acceptable salts thereof. (22) The process in claim 21, wherein the hydrogens at the 6- and 7-positions in the formula (II) have "cis" configuration. (29) A process for producing optically active compounds of cephalosporin analogs represented by the formula (I ' ) EMI77.1 wherein R1 and R have the same significance and R2' represents a halogen atom and X' represents an acyl group represented by the general formula X3CO wherein X3 represents a group represented by the general formula EMI77.2 wherein A1 and B have the same significance and A2" represents amino group, hydroxyl group, carboxyl group or sulfo group and pharmaceutically acceptable salts thereof, which comprises acylating optically inactive compound (II') represented by the formula EMI77.3 (wherein R1 , R2, and R3 have the same significance as defined above) or a functionally equivalent compound with carboxylic acid represented by the formula (VIII) X3COOH (VIII) (wherein X3 represents the following group represented by the formula EMI78.1 wherein A; ; , B and n have the same significance defined above, A2 represents a protected amino group, a hydroxyl group, a protected hydroxyl group, a carboxyl group, a protected carboxyl group, a sulfo group or a protected sulfo group) or wIth reactive derivates of the carboxylic acid and, thereafter, optionally deprotecting the protecting group in the group Z3CO and/or -COOR3, optionally, the obtained diastereomeric mixture being separated by conventional method and optionally, converting to pharmaceutically acceptable salts thereof. (-24) A process for producing optically active compounds of cephalosporin analogs represented by the general formula (IV) EMI78.2 (wherein R6 represents a substituted or unsubstituted saturated or unsaturated six-membered carbocyclic or five- membered heterocyclic group, R1, R2 and R3 have the same meanings defined above, Y represents, a lower alkyl group, a hydroxy group, a carboxy group or an amino group, and the hydrogens at the 6- and 7-positions have cis configuration) and salts thereof, characterized in that &alpha;,&alpha; ;-disubstituted carboxylic acid represented by the general formula (V) EMI78.3 (wherein R6 and Y have the same significance as defined above) or a reactive derivative thereof and an optically inactive compound represented by the general formula (II) or an optically active compound represented by the general formula (Il-i) EMI79.1 (wherein R1, R2 and R3 have the same significance as defined above) are reacted in the presence of (1) a microorganìsm having an ability o producing optically active compounds of the cephalosporin analog represented by the general formula (IV), from the a,-disubstituted carboxylic acid or reactive derivative thereof and the compound represented by the general formula (II) or (II-1) and belonying to the genus Pseudomonas, Xanthomonas, Escherichia, Aeromonas, Achromo- bacter, Arthrobacter, Acetobacter, Alcaligenes, Kluyvera, Gluconobacter, Clostridium, Comamonas, Corynebacterium, Sarcina, Staphylococcus, Spirillum, Bacillus, Flavobacterium, Brevibacterium, Protaminobacter, Beneckea, siìcrococcus, Proteus, Mycoplan2 or Rhodopseudomonas, (2) a culture broth of the microorganism, (3) a treated matter of the culture broth or (4) an enzyme produced by the microorganism and the obtained compound is optionally converted to pharmaceue tically acceptable salt by a conventional method. (25) The process according to claim 24 wherein R4 is a phenyl group, substituent is a hydrogen or p-hydroxy group and Y is an amino group. (26) The process according to claim 25 wherein R6 is a hydrogen or a methyl group, R2 is a hydrogen or a chlorine atom. (27) Pharmaceutical compositions with antimicrobial activity comprising a compound according to any of tne claims 1 to 20 together with conventional diluents and/or carriers and/or adjuvants.

Inventors: HASHIMOTO, YUKIO, HIRATA, TADASHI, KIMURA, KAZUO, KOBAYASHI, SHIGERU, MATSUKUMA, IKUO, OGASA, TAKEHIRO, OHASI, YOICHI, SATO, KIYOSHI, TAKASAWA, SEIGO, YOSHIIE, SHIGEO
Applicants: KYOWA HAKKO KOGYO CO., LTD
Application year: 1980
Main classification: C07D471
IPC codes: C12P17, C07D463